Strain Name:

B6.Cg-Braftm1Mmcm Ptentm1Hwu Tg(Tyr-cre/ERT2)13Bos/BosJ

Stock Number:

013590

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
This tri-allelic mouse model develops induced malignant melanomas following topical application of tamoxifen.

Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating System
Specieslaboratory mouse
GenerationF?+F8 (07-AUG-14)
Generation Definitions
 
Donating Investigator Marcus Bosenberg,   Yale University
Donating Investigator Martin McMahon,   University of California, San Francisco

Description
Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele are viable and fertile, but 25% will develop melanomas with an onset of 2 to 12 months of age. Topical application of tamoxifen results in development of pigmented skin lesions within 21-28 days, and which progress to malignant melanoma. Metastases are detected in lymph nodes and lung. All treated mutant mice developed metastases in regional draining lymph nodes.

The Donating Investigator reports that by 6 months of age, mice hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele, exhibit a 25-60% spontaneous melanoma rate in the absence of 4-hydroxytamoxifen induction, due to "leaky" Cre recombinase expression and activity in a genetic background setting that is conducive to tumor formation.

Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, homozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele develop larger melanoma lesions with tamoxifen application.

Development
The Tyr::CreERT2 transgene was designed with the mouse tyrosinase promoter/enhancer regions upstream of a tamoxifen/4-hydroxytamoxifen-inducible CreERT2 fusion gene (Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain). This transgene was microinjected into FVB/NJ fertilized oocytes. Mice from founder line 13 were found to have melanocyte specific cre activity and were backcrossed to C57BL/6J mice for at least 11 generations. Subsequently, the congenic strain was crossed to B6.129S4-Ptentm1Hwu and maintained as a double homozygote colony. The mice were then crossed to B6.129P2-Braftm1Mmcm mice to generate these triple mutant mice.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Braftm1Mmcm allele
017837   B6.129P2(Cg)-Braftm1Mmcm/J
View Strains carrying   Braftm1Mmcm     (1 strain)

Strains carrying   Ptentm1Hwu allele
006440   B6.129S4-Ptentm1Hwu/J
004597   C;129S4-Ptentm1Hwu/J
View Strains carrying   Ptentm1Hwu     (2 strains)

Strains carrying   Tg(Tyr-cre/ERT2)13Bos allele
012328   B6.Cg-Tg(Tyr-cre/ERT2)13Bos/J
View Strains carrying   Tg(Tyr-cre/ERT2)13Bos     (1 strain)

Strains carrying other alleles of Braf
006373   129-Braftm1Sva/J
View Strains carrying other alleles of Braf     (1 strain)

Strains carrying other alleles of Tyr
000090   129S1/Sv-Oca2+ Tyr+ KitlSl-J/J
000091   129T1/Sv-Oca2+ Tyrc-ch Dnd1Ter/J
005445   A.B6 Tyr+-Cybanmf333/J
005012   A.B6 Tyr+-Myo5ad-l31J/J
002565   A.B6-Tyr+/J
001017   AKXD10/TyJ
000765   AKXD13/TyJ
000954   AKXD15/TyJ
000958   AKXD16/TyJ
001093   AKXD18/TyJ
001062   AKXD21/TyJ
000947   AKXD22/TyJ
000969   AKXD24/TyJ
000777   AKXD6/TyJ
000763   AKXD9/TyJ
000409   B10.129P-H1b Hbbd Tyrc Ea7a/(5M)oSnJ
000418   B10.129P-H1b Tyrc Hbbd/(5M)nSnJ
000432   B10.C-H1b Hbbd Tyrc/(41N)SnJ
000580   B10.D2/nSn-Tyrc-4J/J
000822   B6 x 129S1/SvEi Oca2+ Tyr+-Vsx2or-J/J
000578   B6 x STOCK Tyrc-ch Bmp5se +/+ Myo6sv/J
017614   B6(Cg)-Tyrc-2J Tg(UBC-mCherry)1Phbs/J
000058   B6(Cg)-Tyrc-2J/J
008647   B6.129P2(Cg)-Trpa1tm1.1Kykw Tyrc-2J/J
000383   B6.C-Tyrc H1b Hbbd/ByJ
003819   B6.Cg-Per2tm1Brd Tyrc-Brd/J
023429   B6.Cg-Tyrc-2J Cdkn1atm1Hpw/J
007484   B6.Cg-Tyrc-2J Tg(Tyr)3412ARpw Tg(Sry-EGFP)92Ei/EiJ
000035   B6.Cg-Tyrc-J/J
000104   B6.Cg-Tyrc-h/J
005349   B6.Cg-awag Tyrc-2J/GrsrJ
000054   B6.D2-Tyrc-p/J
023428   B6;129X1-Tyrc-2J Cdkn1atm2Hpw/J
000899   C.B6-Tyr+ Hbbs/J
000339   C3H/HeJ-Tyrc-9J/J
001294   C3H/HeJ-Tyrc-a/J
001002   C57BL/10SnJ-Tyrc-11J/J
021999   C57BL/6NJ-Tyrem3J/GrsrJ
012257   CB6-Tg(Tyr-TAg)BJjw/Mmjax
001006   CBA/J-Tyrc-10J/J
000657   CE/J
000619   FS/EiJ
004624   FVB.129P2-Pde6b+ Tyrc-ch Fmr1tm1Cgr/J
004828   FVB.129P2-Pde6b+ Tyrc-ch/AntJ
007483   FVB.Cg-Tg(Tyr)3412ARpw Tg(Sry-EGFP)92Ei/EiJ
017387   FVB/N-Abce1Tg(Tyr)2295G-2b3Ove/Mmjax
017378   FVB/N-AclyTgTn(sb-cHS4,Tyr)2517BOve/Mmjax
017416   FVB/N-Atad2bTg(Tyr)2295B-4Ove/Mmjax
017369   FVB/N-Casc5Tg(Tyr)2397HOve/Mmjax
017411   FVB/N-CbfbTgTn(sb-cHS4,Tyr)2512E-2Ove/Mmjax
017389   FVB/N-Ccdc174Tg(Tyr)2401AOve/Mmjax
017398   FVB/N-Cct3Tg(Tyr)2423AOve/Mmjax
017363   FVB/N-Chchd3TgTn(sb-cHS4,Tyr)2503C-1bOve/Mmjax
017437   FVB/N-Ckap5TgTn(sb-cHS4,Tyr)2320F-1Ove/J
017415   FVB/N-Cks2TgTn(sb-cHS4,Tyr)2525F-2Ove/Mmjax
017418   FVB/N-Cnpy4Tg(Tyr)2356C-2a1Ove/Mmjax
016870   FVB/NJ-Ap2b1Tg(Tyr)427Ove/EtevJ
000494   J.Cg-Oca2+ Tyr+ Lystbg/J
002281   NFS.C58-Tyr+/J
004304   NOD.CBALs-Tyr+/LtJ
000271   SH1/LeJ
001759   STOCK A Tyrc Sha/J
000306   STOCK Dll3pu + Tyrc-ch/+ Oca2p Tyrc-ch/J
018129   STOCK Fah1R Tyrc/RJ
000006   STOCK Hk Tyrc/J
014173   STOCK Omptm1.1(COP4*/EYFP)Tboz/J
000206   STOCK a/a Tyrc-h/J
View Strains carrying other alleles of Tyr     (67 strains)

Strains carrying other alleles of cre
004337   129(Cg)-Foxg1tm1(cre)Skm/J
008569   129-Alpltm1(cre)Nagy/J
017611   129-Mcm2tm1(cre/ERT2)Scpr/J
005989   129;FVB-Tg(PTH-cre)4167Slib/J
007179   129S.Cg-Tg(UBC-cre/ERT2)1Ejb/J
007915   129S.FVB-Tg(Amh-cre)8815Reb/J
003328   129S/Sv-Tg(Prm-cre)58Og/J
004302   129S1/Sv-Hprttm1(cre)Mnn/J
022137   129S4.Cg-Tg(Wnt1-cre)2Sor/J
003960   129S6-Tg(Prnp-GFP/cre)1Blw/J
008523   129S6.Cg-Tg(NPHS2-cre)295Lbh/BroJ
009575   B6(129S4)-Et(cre/ERT2)119Rdav/J
009580   B6(129S4)-Et(cre/ERT2)1382Rdav/J
012688   B6(129S4)-Et(cre/ERT2)13866Rdav/J
009581   B6(129S4)-Et(cre/ERT2)1642Rdav/J
009582   B6(129S4)-Et(cre/ERT2)1645Rdav/J
009583   B6(129S4)-Et(cre/ERT2)1957Rdav/J
009584   B6(129S4)-Et(cre/ERT2)2007Rdav/J
009585   B6(129S4)-Et(cre/ERT2)2047Rdav/J
009574   B6(129S4)-Et(cre/ERT2)21Rdav/J
009577   B6(129S4)-Et(cre/ERT2)296Rdav/J
009578   B6(129S4)-Et(cre/ERT2)398Rdav/J
009573   B6(129S4)-Et(cre/ERT2)4Rdav/J
010688   B6(129S4)-Et(cre/ERT2)6691Rdav/J
010689   B6(129S4)-Et(cre/ERT2)6959Rdav/J
010690   B6(129S4)-Et(cre/ERT2)7089Rdav/J
010691   B6(129S4)-Et(cre/ERT2)7149Rdav/J
010692   B6(129S4)-Et(cre/ERT2)7381Rdav/J
010693   B6(129S4)-Et(cre/ERT2)8120Rdav/J
010694   B6(129S4)-Et(cre/ERT2)8131Rdav/J
009579   B6(129S4)-Et(cre/ERT2)837Rdav/J
010695   B6(129S4)-Et(cre/ERT2)9699Rdav/J
009587   B6(129S4)-Et(icre)1402Rdav/J
009588   B6(129S4)-Et(icre)1470Rdav/J
009589   B6(129S4)-Et(icre)1555Rdav/J
009586   B6(129S4)-Et(icre)754Rdav/J
010696   B6(129S4)-Et(icre/ERT2)10596Rdav/J
010697   B6(129S4)-Et(icre/ERT2)10727Rdav/J
012689   B6(129S4)-Et(icre/ERT2)14163Rdav/J
012690   B6(129S4)-Et(icre/ERT2)14208Rdav/J
012694   B6(129S4)-Et(icre/ERT2)14915Rdav/J
012687   B6(129S4)-Tg(SYN1-icre/mRFP1)9934Rdav/J
022356   B6(129X1)-Tg(Cd4-cre/ERT2)11Gnri/J
010774   B6(Cg)-Calb2tm1(cre)Zjh/J
013730   B6(Cg)-Calb2tm2.1(cre/ERT2)Zjh/J
017562   B6(Cg)-Cd8atm1.1(cre)Koni/J
012704   B6(Cg)-Crhtm1(cre)Zjh/J
010705   B6(Cg)-Dlx5tm1(cre/ERT2)Zjh/J
013048   B6(Cg)-Etv1tm1.1(cre/ERT2)Zjh/J
018448   B6(Cg)-Foxn1tm3(cre)Nrm/J
010776   B6(Cg)-Lhx6tm1(cre/ERT2)Zjh/J
010777   B6(Cg)-Pvalbtm1(cre/ERT2)Zjh/J
010708   B6(Cg)-Ssttm1(cre/ERT2)Zjh/J
016223   B6(Cg)-Tg(Phox2b-cre)3Jke/J
016829   B6(SJL)-Pou5f1tm1.1(cre/Esr1*)Yseg/J
021881   B6.129(Cg)-Arctm1.1(cre/ERT2)Luo/J
018867   B6.129(Cg)-Axin2tm1(cre/ERT2)Rnu/J
021882   B6.129(Cg)-Fostm1.1(cre/ERT2)Luo/J
016959   B6.129(Cg)-Foxp3tm4(YFP/cre)Ayr/J
023055   B6.129(Cg)-Krt12tm3(cre)Wwk/J
008463   B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J
008320   B6.129-Leprtm2(cre)Rck/J
017526   B6.129-Nos1tm1(cre)Mgmj/J
005697   B6.129-Otx1tm4(cre)Asim/J
018938   B6.129-Tac2tm1.1(cre)Qima/J
017769   B6.129-Trpv1tm1(cre)Bbm/J
004146   B6.129-Tg(Pcp2-cre)2Mpin/J
008710   B6.129P2(129S4)-Hprttm10(Ple162-EGFP/cre)Ems/Mmjax
008877   B6.129P2(129S4)-Hprttm12(Ple177-EGFP/cre)Ems/Mmjax
009116   B6.129P2(129S4)-Hprttm16(Ple167-EGFP/cre)Ems/Mmjax
008709   B6.129P2(129S4)-Hprttm9(Ple178-EGFP/cre)Ems/Mmjax
006785   B6.129P2(C)-Cd19tm1(cre)Cgn/J
021160   B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT)Litt/WganJ
006084   B6.129P2(Cg)-Foxg1tm1(cre)Skm/J
010611   B6.129P2(Cg)-Ighg1tm1(IRES-cre)Cgn/J
007770   B6.129P2-Aicdatm1(cre)Mnz/J
008875   B6.129P2-Lgr5tm1(cre/ERT2)Cle/J
016934   B6.129P2-Lgr6tm2.1(cre/ERT2)Cle/J
004781   B6.129P2-Lyz2tm1(cre)Ifo/J
017320   B6.129P2-Pvalbtm1(cre)Arbr/J
016222   B6.129S(Cg)-Id2tm1.1(cre/ERT2)Blh/ZhuJ
017915   B6.129S(Cg)-Pgrtm1.1(cre)Shah/AndJ
013594   B6.129S-Atoh1tm5.1(Cre/PGR)Hzo/J
021794   B6.129S1(Cg)-Ascl3tm1.1(EGFP/cre)Ovi/J
024637   B6.129S1(SJL)-Nkx2-5tm2(cre)Rph/J
006600   B6.129S1-Mnx1tm4(cre)Tmj/J
005628   B6.129S2-Emx1tm1(cre)Krj/J
022510   B6.129S4-Gpr88tm1.1(cre/GFP)Rpa/J
017578   B6.129S4-Mcpt8tm1(cre)Lky/J
003755   B6.129S4-Meox2tm1(cre)Sor/J
007893   B6.129S4-Myf5tm3(cre)Sor/J
005623   B6.129S6-Shhtm2(cre/ERT2)Cjt/J
006878   B6.129S6-Taglntm2(cre)Yec/J
012839   B6.129X1(Cg)-Tnfrsf4tm2(cre)Nik/J
008712   B6.129X1-Twist2tm1.1(cre)Dor/J
006054   B6.C-Tg(CMV-cre)1Cgn/J
020811   B6.C-Tg(Pgk1-cre)1Lni/CrsJ
019148   B6.Cg-Acantm1(cre/ERT2)Crm/J
023530   B6.Cg-Avptm1.1(cre)Hze/J
023531   B6.Cg-Calb1tm1.1(folA/EGFP/cre)Hze/J
006230   B6.Cg-Cebpatm1Dgt Tg(Mx1-cre)1Cgn/J
012360   B6.Cg-Erbb4tm1.1(cre/ERT2)Aibs/J
023676   B6.Cg-Hprttm331(Ple275-icre/ERT2)Ems/Mmjax
023678   B6.Cg-Hprttm333(Ple281-icre/ERT2)Ems/Mmjax
023679   B6.Cg-Hprttm334(Ple279-icre/ERT2)Ems/Mmjax
023680   B6.Cg-Hprttm335(Ple277-icre/ERT2)Ems/Mmjax
023685   B6.Cg-Hprttm340(Ple252-icre/ERT2)Ems/Mmjax
023686   B6.Cg-Hprttm341(Ple273-icre/ERT2)Ems/Mmjax
023688   B6.Cg-Hprttm343(Ple270-icre/ERT2)Ems/Mmjax
022861   B6.Cg-Nxph4tm1.1(cre/ERT2)Hze/J
017763   B6.Cg-Pax7tm1(cre/ERT2)Gaka/J
022862   B6.Cg-Penktm1.1(cre/ERT2)Hze/J
012358   B6.Cg-Pvalbtm1.1(cre)Aibs/J
022863   B6.Cg-Pvalbtm5.1(cre/folA)Hze/J
005622   B6.Cg-Shhtm1(EGFP/cre)Cjt/J
022865   B6.Cg-Trib2tm1.1(cre/ERT2)Hze/J
022762   B6.Cg-Zfp335tm1.2Caw Emx1tm1(cre)Krj/J
017346   B6.Cg-Tg(A930038C07Rik-cre)1Aibs/J
006149   B6.Cg-Tg(ACTA1-cre)79Jme/J
003574   B6.Cg-Tg(Alb-cre)21Mgn/J
006881   B6.Cg-Tg(Aqp2-cre)1Dek/J
011104   B6.Cg-Tg(Atoh1-cre)1Bfri/J
004682   B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J
008520   B6.Cg-Tg(CD2-cre)4Kio/J
009350   B6.Cg-Tg(CDX2-cre)101Erf/J
009352   B6.Cg-Tg(CDX2-cre*)189Erf/J
005359   B6.Cg-Tg(Camk2a-cre)T29-1Stl/J
022071   B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ
012237   B6.Cg-Tg(Cdh16-cre)91Igr/J
016241   B6.Cg-Tg(Col1a1-cre/ERT2)1Crm/J
016237   B6.Cg-Tg(Col1a2-cre/ERT)7Cpd/J
006368   B6.Cg-Tg(Cr2-cre)3Cgn/J
008538   B6.Cg-Tg(Cspg4-cre/Esr1*)BAkik/J
006663   B6.Cg-Tg(Eno2-cre)39Jme/J
005069   B6.Cg-Tg(Fabp4-cre)1Rev/J
012712   B6.Cg-Tg(Fev-cre)1Esd/J
012849   B6.Cg-Tg(GFAP-cre/ERT2)505Fmv/J
012886   B6.Cg-Tg(Gfap-cre)73.12Mvs/J
024098   B6.Cg-Tg(Gfap-cre)77.6Mvs/2J
009642   B6.Cg-Tg(Gh1-cre)1Sac/J
024474   B6.Cg-Tg(Il9-cre)#Stck/J
003573   B6.Cg-Tg(Ins2-cre)25Mgn/J
008068   B6.Cg-Tg(Itgax-cre)1-1Reiz/J
008781   B6.Cg-Tg(Kap-cre)29066/2Sig/J
012837   B6.Cg-Tg(Lck-cre)3779Nik/J
003802   B6.Cg-Tg(Lck-cre)548Jxm/J
006889   B6.Cg-Tg(Lck-cre)I540Jxm/J
009643   B6.Cg-Tg(Lhb-cre)1Sac/J
008330   B6.Cg-Tg(Mc4r-cre)25Rck/J
003556   B6.Cg-Tg(Mx1-cre)1Cgn/J
007742   B6.Cg-Tg(Myh11-cre,-EGFP)2Mik/J
008205   B6.Cg-Tg(NPHS2-cre)295Lbh/J
003771   B6.Cg-Tg(Nes-cre)1Kln/J
010536   B6.Cg-Tg(Pcp2-cre)3555Jdhu/J
005975   B6.Cg-Tg(Plp1-cre/ERT)3Pop/J
008827   B6.Cg-Tg(Prdm1-cre)1Masu/J
005584   B6.Cg-Tg(Prrx1-cre)1Cjt/J
003967   B6.Cg-Tg(Rbp3-cre)528Jxm/J
021614   B6.Cg-Tg(S100A8-cre,-EGFP)1Ilw/J
008454   B6.Cg-Tg(Sox2-cre)1Amc/J
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
003966   B6.Cg-Tg(Syn1-cre)671Jxm/J
017491   B6.Cg-Tg(Tagln-cre)1Her/J
004128   B6.Cg-Tg(Tek-cre)12Flv/J
008863   B6.Cg-Tg(Tek-cre)1Ywa/J
008601   B6.Cg-Tg(Th-cre)1Tmd/J
007606   B6.Cg-Tg(Thy1-cre/ERT2,-EYFP)AGfng/J
008085   B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J
008610   B6.Cg-Tg(Vav1-cre)A2Kio/J
004586   B6.Cg-Tg(Vil-cre)997Gum/J
021504   B6.Cg-Tg(Vil1-cre)1000Gum/J
008735   B6.Cg-Tg(Wap-cre)11738Mam/JKnwJ
009614   B6.Cg-Tg(Wfs1-cre/ERT2)2Aibs/J
009107   B6.Cg-Tg(Wnt1-cre)11Rth Tg(Wnt1-GAL4)11Rth/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
016832   B6.FVB(129)-Tg(Alb1-cre)1Dlr/J
005657   B6.FVB(129)-Tg(Myh6-cre/Esr1*)1Jmk/J
024688   B6.FVB(129S)-Tg(Pax6-GFP/cre)1Rilm/J
006475   B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J
006451   B6.FVB(129X1)-Tg(Sim1-cre)1Lowl/J
006333   B6.FVB(Cg)-Tg(Neurog3-cre)C1Able/J
014643   B6.FVB-Tg(CMA1-cre)6Thhe/J
006137   B6.FVB-Tg(Cdh5-cre)7Mlia/J
018980   B6.FVB-Tg(Ddx4-cre)1Dcas/KnwJ
003724   B6.FVB-Tg(EIIa-cre)C5379Lmgd/J
011069   B6.FVB-Tg(Gh1-cre)bKnmn/J
011038   B6.FVB-Tg(Myh6-cre)2182Mds/J
014647   B6.FVB-Tg(Pdx1-cre)6Tuv/J
010714   B6.FVB-Tg(Pomc-cre)1Stl/J
022791   B6.FVB-Tg(Rorc-cre)1Litt/J
017535   B6.FVB-Tg(Slc32a1-cre)2.1Hzo/FrkJ
017490   B6.FVB-Tg(Stra8-cre)1Reb/LguJ
024670   B6.FVB-Tg(Ucp1-cre)1Evdr/J
003394   B6.FVB-Tg(Zp3-cre)3Mrt/J
006660   B6.SJL-Slc6a3tm1.1(cre)Bkmn/J
003552   B6129-Tg(Wap-cre)11738Mam/J
023161   B6129S-Tg(Foxp3-EGFP/cre)1aJbs/J
021961   B6;129-Abcg2tm3.1(cre/ERT2)Bsor/J
010531   B6;129-Bmi1tm1(cre/ERT)Mrc/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
004847   B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
010557   B6;129-Gt(ROSA)26Sortm3(rtTA,tetO-cre/ERT)Nat/J
010529   B6;129-Myf5tm1(cre)Mrc/J
010528   B6;129-Myf6tm2(cre)Mrc/J
024475   B6;129-Myod1tm1.1(cre/ERT,TVA)Gcg/J
008363   B6;129-Nefltm1(cre/ERT)Nat/J
017525   B6;129-Ntstm1(cre)Mgmj/J
005549   B6;129-Pax3tm1(cre)Joe/J
012476   B6;129-Pax7tm2.1(cre/ERT2)Fan/J
009600   B6;129-Six2tm3(EGFP/cre/ERT2)Amc/J
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008531   B6;129-Vamp2tm1(cre/ERT)Nat/J
017968   B6;129-Tg(Cdh5-cre)1Spe/J
024860   B6;129-Tg(Drd1a-cre)120Mxu/Mmjax
010988   B6;129P-Cyp11a1tm1(GFP/cre)Pzg/J
010985   B6;129P-Klf3tm1(cre/ERT2)Pzg/J
008529   B6;129P-Tg(Neurog1-cre/ERT2)1Good/J
015854   B6;129P2-Foxl2tm1(GFP/cre/ERT2)Pzg/J
012601   B6;129P2-Lyve1tm1.1(EGFP/cre)Cys/J
006668   B6;129P2-Omptm4(cre)Mom/MomJ
008069   B6;129P2-Pvalbtm1(cre)Arbr/J
012373   B6;129S-Hoxb1tm1(cre)Og/J
014541   B6;129S-Nos1tm1.1(cre/ERT2)Zjh/J
024234   B6;129S-Oxttm1.1(cre)Dolsn/J
022864   B6;129S-Rasgrf2tm1(cre/folA)Hze/J
023526   B6;129S-Rorbtm1.1(cre)Hze/J
023527   B6;129S-Slc17a7tm1.1(cre)Hze/J
023525   B6;129S-Snap25tm2.1(cre)Hze/J
010987   B6;129S-Sox18tm1(GFP/cre/ERT2)Pzg/J
017593   B6;129S-Sox2tm1(cre/ERT2)Hoch/J
021877   B6;129S-Tac1tm1.1(cre)Hze/J
021878   B6;129S-Tac2tm1.1(cre)Hze/J
017685   B6;129S-Wisp3tm1(cre)Mawa/J
007001   B6;129S-Tg(UBC-cre/ERT2)1Ejb/J
009388   B6;129S1-Osr2tm2(cre)Jian/J
014551   B6;129S4-Dlx1tm1(cre/ERT2)Zjh/J
012463   B6;129S4-Foxd1tm1(GFP/cre)Amc/J
012464   B6;129S4-Foxd1tm2(GFP/cre/ERT2)Amc/J
011105   B6;129S4-Olig1tm1(cre)Rth/J
009576   B6;129S4-Et(cre/ERT2)278Rdav/J
006410   B6;129S6-Chattm2(cre)Lowl/J
024948   B6;129S6-Gdnftm1(cre/ERT2)Cos/J
012362   B6;129S6-Tg(Camk2a-cre/ERT2)1Aibs/J
017495   B6;129S7-Crim1tm1(GFP/cre/ERT2)Pzg/J
014638   B6;129X1-Cldn6tm1(cre/ERT2)Dam/J
009616   B6;C3-Tg(A930038C07Rik-cre)4Aibs/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
008844   B6;C3-Tg(Ctgf-cre)2Aibs/J
008839   B6;C3-Tg(Cyp39a1-cre)1Aibs/J
009117   B6;C3-Tg(Cyp39a1-cre)7Aibs/J
008848   B6;C3-Tg(Mybpc1-cre)2Aibs/J
009111   B6;C3-Tg(Scnn1a-cre)1Aibs/J
009112   B6;C3-Tg(Scnn1a-cre)2Aibs/J
009613   B6;C3-Tg(Scnn1a-cre)3Aibs/J
009103   B6;C3-Tg(Wfs1-cre/ERT2)3Aibs/J
025806   B6;CBA-Tg(Gsx2-cre)1Kess/J
025807   B6;CBA-Tg(Sox10-cre)1Wdr/J
024507   B6;CBA-Tg(Tbx21-cre)1Dlc/J
017494   B6;D-Tg(Tshz3-GFP/cre)43Amc/J
024926   B6;D2-Tg(Fshr-cre)1Ldu/J
003466   B6;D2-Tg(Sycp1-cre)4Min/J
014160   B6;DBA-Tg(S100b-EGFP/cre/ERT2)22Amc/J
014159   B6;DBA-Tg(Tmem100-EGFP/cre/ERT2)30Amc/J
015855   B6;DBA-Tg(Upk3a-GFP/cre/ERT2)26Amc/J
010803   B6;FVB-Tg(Adipoq-cre)1Evdr/J
018422   B6;FVB-Tg(Aicda-cre)1Rcas/J
023748   B6;FVB-Tg(Aldh1l1-cre)JD1884Gsat/J
011087   B6;FVB-Tg(Crh-cre)1Kres/J
008533   B6;FVB-Tg(Cspg4-cre)1Akik/J
003734   B6;FVB-Tg(GZMB-cre)1Jcb/J
004426   B6;SJL-Tg(Cga-cre)3Sac/J
003554   B6;SJL-Tg(Col2a1-cre)1Bhr/J
017738   B6;SJL-Tg(Foxl1-cre)1Khk/J
005249   B6;SJL-Tg(Krt1-15-cre/PGR)22Cot/J
007610   B6;SJL-Tg(Thy1-cre/ERT2,-EYFP)VGfng/J
007252   B6Ei.129S4-Tg(Prm-cre)58Og/EiJ
018956   B6N.129P2(B6)-Lyz2tm1(cre)Ifo/J
018958   B6N.129P2-Cd19tm1(cre)Cgn/J
021077   B6N.129S1-Mrgprb4tm3(cre)And/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
017911   B6N.129S6(Cg)-Esr1tm1.1(cre)And/J
019013   B6N.129S6(Cg)-Gt(ROSA)26Sortm2(EGFP/cre)Alj/J
016225   B6N.129S6(Cg)-Scgb1a1tm1(cre/ERT)Blh/J
018974   B6N.B6-Tg(Nr4a1-EGFP/cre)820Khog/J
019021   B6N.Cg-Ccktm1.1(cre)Zjh/J
019022   B6N.Cg-Gad2tm2(cre)Zjh/J
018973   B6N.Cg-Ssttm2.1(cre)Zjh/J
018961   B6N.Cg-Tg(Alb-cre)21Mgn/J
019102   B6N.Cg-Tg(CAG-cre/Esr1*)5Amc/CjDswJ
018966   B6N.Cg-Tg(Camk2a-cre)T29-1Stl/J
018965   B6N.Cg-Tg(Fabp4-cre)1Rev/J
017310   B6N.Cg-Tg(Hsd17b1-icre/ERT2)3Casa/J
018960   B6N.Cg-Tg(Ins2-cre)25Mgn/J
018967   B6N.Cg-Tg(Itgax-cre)1-1Reiz/J
018964   B6N.Cg-Tg(KRT14-cre)1Amc/J
019103   B6N.Cg-Tg(Nes-cre)1Kln/CjDswJ
014094   B6N.Cg-Tg(Sox2-cre)1Amc/J
018968   B6N.Cg-Tg(Vav1-cre)A2Kio/J
018963   B6N.Cg-Tg(Vil-cre)997Gum/J
018972   B6N.FVB(B6)-Tg(Myh6-cre)2182Mds/J
019099   B6N.FVB-Tg(ACTB-cre)2Mrt/CjDswJ
019509   B6N.FVB-Tg(BGLAP-cre)1Clem/J
023047   B6N.FVB-Tg(Dmp1-cre)1Jqfe/BwdJ
017927   B6N.FVB-Tg(Mpz-cre)26Mes/J
010550   B6N.FVB-Tg(Penk-glc-2-cre/ERT2)2And/J
017743   B6N;129S-Prom1tm1(cre/ERT2)Gilb/J
003465   BALB/c-Tg(CMV-cre)1Cgn/J
012641   BALB/c-Tg(S100a4-cre)1Egn/YunkJ
010612   C.129P2(Cg)-Ighg1tm1(IRES-cre)Cgn/J
017353   C.129S4(B6)-Il13tm1(YFP/cre)Lky/J
017582   C.129S4(B6)-Mcpt8tm1(cre)Lky/J
004126   C.Cg-Cd19tm1(cre)Cgn Ighb/J
005673   C.Cg-Tg(Mx1-cre)1Cgn/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
009155   C57BL/6-Cldn6tm1(cre)Dkwu/J
017557   C57BL/6-Tg(BEST1-cre)1Jdun/J
016097   C57BL/6-Tg(Car1-cre)5Flt/J
011086   C57BL/6-Tg(Cck-cre)CKres/J
008766   C57BL/6-Tg(Cd8a-cre)1Itan/J
006474   C57BL/6-Tg(Grik4-cre)G32-4Stl/J
008314   C57BL/6-Tg(HBB-cre)12Kpe/J
008870   C57BL/6-Tg(Hspa2-cre)1Eddy/J
023426   C57BL/6-Tg(Kiss1-cre)J2-4Cfe/J
016261   C57BL/6-Tg(Nes-cre/ERT2)KEisc/J
012906   C57BL/6-Tg(Nes-cre/Esr1*)1Kuan/J
016617   C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J
020287   C57BL/6-Tg(Pbsn-cre/Esr1*)14Abch/J
013148   C57BL/6-Tg(Pdgfra-cre)1Clc/J
008535   C57BL/6-Tg(Pf4-cre)Q3Rsko/J
024034   C57BL/6-Tg(Pmch-cre)1Rck/J
016583   C57BL/6-Tg(Slc6a3-icre/ERT2)2Gloss/J
006888   C57BL/6-Tg(Zp3-cre)1Gwh/J
003651   C57BL/6-Tg(Zp3-cre)93Knw/J
021119   C57BL/6J-Tg(Dlx2-cre,-mCherry)4Grsr/GrsrJ
021423   C57BL/6J-Tg(Dlx2-cre,-mCherry)9Grsr/GrsrJ
007567   C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J
018895   C57BL/6J-Tg(Krt6,-cre,-Cerulean)1Grsr/Grsr
018896   C57BL/6J-Tg(Krt6,-cre,-Cerulean)2Grsr/Grsr
018898   C57BL/6J-Tg(Krt6,-cre,-Cerulean)4Grsr/Grsr
018899   C57BL/6J-Tg(Krt6,-cre,-Cerulean)5Grsr/Grsr
021582   C57BL/6J-Tg(Mchr1-cre)1Emf/J
008661   C57BL/6J-Tg(Nkx2-1-cre)2Sand/J
018754   C57BL/6J-Tg(Tbx22,-cre,-mCherry)1Grsr/GrsrJ
019363   C57BL/6J-Tg(Trp63,-cre,-Cerulean)10Grsr/Grsr
018792   C57BL/6J-Tg(Trp63,-cre,-Cerulean)4Grsr/GrsrJ
003650   C57BL/6J-Tg(Zp3-cre)82Knw/KnwJ
018151   C57BL/6N-Krt17tm1(cre,Cerulean)Murr/GrsrJ
023014   C57BL/6N-Tg(Calcrl,cre)4688Nkza/J
012686   C57BL/6N-Tg(Ppp1r2-cre)4127Nkza/J
016582   C57BL/6N-Tg(Slc32a1-icre/ERT2)3Gloss/J
024701   D2.Cg-Tg(Plp1-cre/ERT)3Pop/SjJ
016833   FVB(Cg)-Tg(Alb1-cre)1Dlr/J
012929   FVB(Cg)-Tg(Dhh-cre)1Mejr/J
011034   FVB(Cg)-Tg(Ghrhr-cre)3242Lsk/J
023407   FVB-HhatTg(TFAP2A-cre)1Will/J
006405   FVB-Tg(Ckmm-cre)5Khn/J
006774   FVB-Tg(Col2a1-cre/ERT)KA3Smac/J
021024   FVB-Tg(Csf1r-icre)1Jwp/J
006954   FVB-Tg(Ddx4-cre)1Dcas/J
004600   FVB-Tg(GFAP-cre)25Mes/J
011037   FVB-Tg(Myh6-cre)2182Mds/J
006364   FVB-Tg(Nr5a1-cre)2Lowl/J
008537   FVB-Tg(Tek-cre)2352Rwng/J
019382   FVB.Cg-Myh9tm1.1Gac Tg(NPHS2-cre)295Lbh/Mmjax
014140   FVB.Cg-Myod1tm2.1(icre)Glh/J
006139   FVB.Cg-Tg(ACTA1-cre)79Jme/J
017595   FVB.Cg-Tg(CAG-cre/Esr1*)5Amc/J
006297   FVB.Cg-Tg(Eno2-cre)39Jme/J
018394   FVB.Cg-Tg(KRT5-cre/ERT2)2Ipc/JeldJ
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
003376   FVB/N-Tg(ACTB-cre)2Mrt/J
024384   FVB/N-Tg(AMELX-cre)A1Kul/J
003314   FVB/N-Tg(EIIa-cre)C5379Lmgd/J
017928   FVB/N-Tg(Mpz-cre)26Mes/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
003377   FVB/N-Tg(Zp3-cre)3Mrt/J
023325   FVB;B6-Tg(Pbsn-cre)20Fwan/J
019096   NOD.129P2(B6)-Lyz2tm1(cre)Ifo/NadlJ
013233   NOD.B6-Tg(Itgax-cre,-EGFP)4097Ach/J
013234   NOD.Cg-Tg(Cd4-cre)1Cwi/2AchJ
023972   NOD.Cg-Tg(Ins2-cre/ERT)1Dam/SbwJ
023203   NOD.Cg-Tg(Itgax-cre)1-1Reiz/PesaJ
005732   NOD.Cg-Tg(Lck-cre)548Jxm/AchJ
023973   NOD.Cg-Tg(Neurog3-cre)1Dam/SbwJ
013251   NOD.FVB-Tg(EIIa-cre)C5379Lmgd/J
008694   NOD/ShiLt-Tg(Foxp3-EGFP/cre)1cJbs/J
004986   NOD/ShiLt-Tg(Ins2-cre)3Lt/LtJ
003855   NOD/ShiLt-Tg(Ins2-cre)5Lt/LtJ
004987   NOD/ShiLt-Tg(Ins2-cre)6Lt/LtJ
012899   STOCK Agrptm1(cre)Lowl/J
012882   STOCK Ascl1tm1.1(Cre/ERT2)Jejo/J
012706   STOCK Ccktm1.1(cre)Zjh/J
012710   STOCK Ccktm2.1(cre/ERT2)Zjh/J
010910   STOCK Corttm1(cre)Zjh/J
007916   STOCK En1tm2(cre)Wrst/J
007917   STOCK En1tm7(cre/ESR1)Alj/J
007924   STOCK En2tm4(cre/ERT2)Alj/J
008464   STOCK Foxa2tm2.1(cre/Esr1*)Moon/J
016961   STOCK Foxp3tm9(EGFP/cre/ERT2)Ayr/J
010702   STOCK Gad2tm1(cre/ERT2)Zjh/J
010802   STOCK Gad2tm2(cre)Zjh/J
022135   STOCK Gbx2tm1.1(cre/ERT2)Jyhl/J
007913   STOCK Gli1tm3(cre/ERT2)Alj/J
018903   STOCK Gt(ROSA)26Sortm2(EGFP/cre)Alj/J
024283   STOCK Hcn4tm2.1(cre/ERT2)Sev/J
017606   STOCK Hopxtm2.1(cre/ERT2)Joe/J
008876   STOCK Hprttm11(Ple176-EGFP/cre)Ems/Mmjax
016879   STOCK Il17atm1.1(icre)Stck/J
024242   STOCK Isl1tm1(cre)Sev/J
018976   STOCK Kdrtm1(cre)Sato/J
017701   STOCK Kiss1tm1.1(cre/EGFP)Stei/J
018418   STOCK Lrig1tm1.1(cre/ERT2)Rjc/J
007022   STOCK Mnx1tm4(cre)Tmj Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb/J
004192   STOCK Mttptm2Sgy Ldlrtm1Her Apobtm2Sgy Tg(Mx1-cre)1Cgn/J
023342   STOCK Myf5tm1(cre/Esr1*)Trdo/J
024713   STOCK Myl1tm1(cre)Sjb/J
014180   STOCK Myocdtm1(cre)Jomm/J
014552   STOCK Nkx2-1tm1.1(cre/ERT2)Zjh/J
017536   STOCK Nkx6-2tm1(cre/ERT2)Fsh/J
006953   STOCK Notch1tm3(cre)Rko/J
006677   STOCK Olfr151tm28(cre)Mom/MomJ
011103   STOCK Olig2tm2(TVA,cre)Rth/J
009061   STOCK Osr1tm1(EGFP/cre/ERT2)Amc/J
010530   STOCK Pax7tm1(cre)Mrc/J
017569   STOCK Polr2atm1(cre/ERT2)Bbd E4f1tm1.1Llca/J
017585   STOCK Polr2atm1(cre/ERT2)Bbd/J
022757   STOCK Prg4tm1(GFP/cre/ERT2)Abl/J
019378   STOCK Ptf1atm2(cre/ESR1)Cvw/J
016963   STOCK Slc17a6tm2(cre)Lowl/J
016962   STOCK Slc32a1tm2(cre)Lowl/J
013044   STOCK Ssttm2.1(cre)Zjh/J
012719   STOCK Tgfb3tm1(cre)Vk/J
012620   STOCK Trp53tm1Brd Brca1tm1Aash Tg(LGB-cre)74Acl/J
008813   STOCK Trpa1tm2Kykw Tg(CAG-cre/Esr1*)5Amc/J
010908   STOCK Viptm1(cre)Zjh/J
010911   STOCK Wt1tm1(EGFP/cre)Wtp/J
010912   STOCK Wt1tm2(cre/ERT2)Wtp/J
012691   STOCK Et(icre/ERT2)14374Rdav/J
012692   STOCK Et(icre/ERT2)14602Rdav/J
012693   STOCK Et(icre/ERT2)14624Rdav/J
007684   STOCK Tg(Atoh1-cre/Esr1*)14Fsh/J
008783   STOCK Tg(CAG-cre/Esr1*)5Amc Smn1tm3(SMN2/Smn1)Mrph Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb/J
004453   STOCK Tg(CAG-cre/Esr1*)5Amc/J
009615   STOCK Tg(Cartpt-cre)1Aibs/J
017336   STOCK Tg(Cd4-cre)1Cwi/BfluJ
005105   STOCK Tg(Chx10-EGFP/cre,-ALPP)2Clc/J
008861   STOCK Tg(Ela1-Cre/ERT2)1Stof/J
008852   STOCK Tg(En2-cre)22Alj/J
005938   STOCK Tg(Eno2-cre)39Jme/J
022763   STOCK Tg(Eno2-cre/ERT2)1Pohlk/J
011062   STOCK Tg(Gdf9-cre)5092Coo/J
012841   STOCK Tg(Ggt1-cre)M3Egn/J
021207   STOCK Tg(Gnrh1-cre)1Dlc/J
017981   STOCK Tg(Hoxb6-cre)#Mku/J
004692   STOCK Tg(Hoxb7-cre)13Amc/J
014600   STOCK Tg(I12b-cre/ERT2,-ALPP)37Fsh/J
008122   STOCK Tg(Ins2-cre/ERT)1Dam/J
004782   STOCK Tg(KRT14-cre)1Amc/J
005107   STOCK Tg(KRT14-cre/ERT)20Efu/J
008582   STOCK Tg(Kcnc2-Cre)K128Stl/LetJ
017836   STOCK Tg(LGB-cre)74Acl/J
003551   STOCK Tg(MMTV-cre)1Mam/J
003553   STOCK Tg(MMTV-cre)4Mam/J
002527   STOCK Tg(Mx1-cre)1Cgn/J
009074   STOCK Tg(Myh6-cre)1Jmk/J
005650   STOCK Tg(Myh6-cre/Esr1*)1Jmk/J
009102   STOCK Tg(Nefh-cre)12Kul/J
002858   STOCK Tg(Nes-cre)1Wme/J
002859   STOCK Tg(Nes-cre)2Wme/J
012859   STOCK Tg(Neurog1-cre)1Jejo/J
005667   STOCK Tg(Neurog3-cre)C1Able/J
008119   STOCK Tg(Neurog3-cre/Esr1*)1Dam/J
012462   STOCK Tg(Nr5a1-cre)7Lowl/J
014158   STOCK Tg(Pax4-cre)1Dam/J
024578   STOCK Tg(Pax6-GFP/cre)1Rilm/J
006207   STOCK Tg(Pcp2-cre)1Amc/J
014099   STOCK Tg(Pmch-cre)1Lowl/J
005965   STOCK Tg(Pomc1-cre)16Lowl/J
012452   STOCK Tg(Rr5-GFP/cre)1Sapc/J
006395   STOCK Tg(Sim1-cre)1Lowl/J
009606   STOCK Tg(Six2-EGFP/cre)1Amc/J
018147   STOCK Tg(Slc17a8-icre)1Edw/SealJ
012586   STOCK Tg(Slc1a3-cre/ERT)1Nat/J
004783   STOCK Tg(Sox2-cre)1Amc/J
008208   STOCK Tg(Stra8-cre)1Reb/J
016236   STOCK Tg(TCF/Lef1-cre/ERT2)1Dje/J
004746   STOCK Tg(Tagln-cre)1Her/J
012708   STOCK Tg(Thy1-cre/ERT2,-EYFP)HGfng/PyngJ
024240   STOCK Tg(Tnnt2-cre)5Blh/JiaoJ
016584   STOCK Tg(Tph2-icre/ERT2)6Gloss/J
003829   STOCK Tg(Wnt1-cre)11Rth Tg(Wnt1-GAL4)11Rth/J
008851   STOCK Tg(Wnt1-cre/ERT)1Alj/J
018281   STOCK Tg(Wnt7a-EGFP/cre)#Bhr/Mmjax
008199   STOCK Tg(dlx6a-cre)1Mekk/J
002471   STOCK Tg(hCMV-cre)140Sau/J
023724   STOCK Tg(mI56i-cre,EGFP)1Kc/J
006224   STOCK Tg(tetO-cre)1Jaw/J
View Strains carrying other alleles of cre     (498 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence
      Skin Cancers
      Skin Cancers: Induced
Other
      tumor metastasis

Research Tools
Cre-lox System
      loxP-flanked Sequences
      Cre Recombinase Expression: Inducible

cre related

Research Tools
Cre-lox System
Genetics Research
      Mutagenesis and Transgenesis
      Mutagenesis and Transgenesis: Cre-lox System

Ptentm1Hwu related

Cancer Research
Tumor Suppressor Genes

Cell Biology Research
Cell Cycle Regulation

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Braftm1Mmcm
Allele Name targeted mutation 1, Martin McMahon
Allele Type Targeted (Conditional ready (e.g. floxed), No functional change)
Common Name(s) BRAFF-V600E; BrafCA;
Mutation Made By Martin McMahon,   University of California, San Francisco
Strain of Origin129P2/OlaHsd
Site of Expressionintranasal instillation of an adenovirus expressing Cre recombinase results in benign lung tumors that only rarely progress to adenocarcinoma.
Expressed Gene BRAF, B-Raf proto-oncogene, serine/threonine kinase, human
Molecular Note A targeting vector was designed to insert a loxP site and the human BRAF cDNA covering exons 15-18 into intron 14, along with a floxed neo cassette. A modified exon 15 was engineered into the vector to encode Braf and a silent XbaI restriction site. RT-PCR confirmed that mutant transcript was expressed at the same level as wild-type, and that the V600E mutation was not detected. [MGI Ref ID J:121715]
 
Gene Symbol and Name Braf, Braf transforming gene
Chromosome 6
Gene Common Name(s) 9930012E13Rik; AA120551; AA387315; AA473386; B-RAF1; BRAF1; Braf transforming gene 2; Braf-2; Braf2; C87398; D6Ertd631e; DNA segment, Chr 6, ERATO Doi 631, expressed; NS7; RAFB1; RIKEN cDNA 9930012E13 gene; expressed sequence AA120551; expressed sequence AA387315; expressed sequence AA473386; expressed sequence C87398;
 
Allele Symbol Ptentm1Hwu
Allele Name targeted mutation 1, Hong Wu
Allele Type Targeted (Conditional ready (e.g. floxed), No functional change)
Common Name(s) PTENF; Ptenex5lox; Ptenfl; Ptenflox; Ptenfx; Ptenlox; Ptenloxp;
Mutation Made By Hong Wu,   UCLA
Strain of Origin129S4/SvJae
ES Cell Line NameLW1
ES Cell Line Strain129S4/SvJae
Site of ExpressionPten is a widely expressed tumor suppresser gene.
Gene Symbol and Name Pten, phosphatase and tensin homolog
Chromosome 19
Gene Common Name(s) 10q23del; 2310035O07Rik; A130070J02Rik; AI463227; B430203M17Rik; BZS; CWS1; DEC; GLM2; MHAM; MMAC1; Mmac; PTEN1; RIKEN cDNA 2310035O07 gene; RIKEN cDNA A130070J02 gene; RIKEN cDNA B430203M17 gene; TEP1; expressed sequence AI463227;
General Note Phenotypic Similarity to Human Syndrome: Chronic intestinal pseudoobstruction J:155110.

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor of the testis (GCTT) J:149060.

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor (GCT) J:142150.

Phenotypic Similarity to Human Syndrome: Glioblastoma J:172585.

Phenotypic Similarity to Human Syndrome: B cell lymphoma J:166155.

Phenotypic Similarity to Human Syndrome: Astrocytoma J:134611

Phenotypic Similarity to Human Syndrome: Thyroid Carcinoma (J:177181)

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor (GCT) J:186144

Phenotypic Similarity to Human Syndrome: Granulosa cell tumor of the testis (GCTT) J:186144

Phenotypic Similarity to Human Syndrome: PTEN Hamartoma Tumor Syndrome (see OMIM:601728 Phosphatase And Tensin Homolog; PTEN) J:199362

Molecular Note A loxP flanked hygromycin resistance cassette was inserted 5' to exon 5, and a single loxP site was inserted 3' to exon 5, which encodes the phosphatase domain. The hygromycin cassette was removed in ES cells by transient Cre recombinase expression prior to the production of chimeric mice, leaving a single loxP site in place of the cassette. These insertions do not appear to have any effect on the normal function of the gene. [MGI Ref ID J:75117]
 
Allele Symbol Tg(Tyr-cre/ERT2)13Bos
Allele Name transgene insertion 13, Marcus Bosenberg
Allele Type Transgenic (Inducible, Recombinase (cre or Flp) expressing)
Common Name(s) Tyr::CreER; Tyr::CreERT2;
Mutation Made By Marcus Bosenberg,   Yale University
Strain of OriginFVB
Site of Expressiontamoxifen-induced Cre activity is expressed in cutaneous melanocytes.
Expressed Gene cre, cre recombinase, bacteriophage P1
Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence.
Promoter Tyr, tyrosinase, mouse, laboratory
Driver Note Tyr
Inducible Note induced by tamoxifen
Molecular Note This transgene consists of a 5.5 kb fragment of the Tyr promoter and a 3.6 kb fragment of the Tyr enhancer driving expression of a tamoxifen inducible form of cre recombinase. 3 lines were generated which all showed tamoxifen-inducible Cre activity in cutaneous melanocytes. This is a representative record for all 3 lines. [MGI Ref ID J:110143]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Braftm1Mmcm, High Resolution Melting
Braftm1Mmcm, Standard PCR
Generic Cre Melt Curve Analysis,

Probe


Generic Cre Melt Curve Analysis, Melt Curve Analysis
Generic Cre Quantitative PCR, QPCR
Generic Cre, Standard PCR
Ptentm1Hwu, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE Jr; You MJ; DePinho RA; McMahon M; Bosenberg M. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544-52. [PubMed: 19282848]  [MGI Ref ID J:151023]

Additional References

Braftm1Mmcm related

Aytes A; Mitrofanova A; Lefebvre C; Alvarez MJ; Castillo-Martin M; Zheng T; Eastham JA; Gopalan A; Pienta KJ; Shen MM; Califano A; Abate-Shen C. 2014. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5):638-51. [PubMed: 24823640]  [MGI Ref ID J:210591]

Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM. 2014. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509(7501):492-6. [PubMed: 24717435]  [MGI Ref ID J:210437]

Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765]  [MGI Ref ID J:193498]

Charles RP; Iezza G; Amendola E; Dankort D; McMahon M. 2011. Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse. Cancer Res 71(11):3863-71. [PubMed: 21512141]  [MGI Ref ID J:172205]

Charles RP; Silva J; Iezza G; Phillips WA; McMahon M. 2014. Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Mol Cancer Res 12(7):979-86. [PubMed: 24770869]  [MGI Ref ID J:211098]

Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M. 2012. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2(8):685-93. [PubMed: 22628411]  [MGI Ref ID J:193065]

Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M. 2011. beta-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 20(6):741-54. [PubMed: 22172720]  [MGI Ref ID J:178598]

Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21(4):379-84. [PubMed: 17299132]  [MGI Ref ID J:121715]

Gonzalez-Sanchez E; Martin-Caballero J; Flores JM; Hernandez-Losa J; Cortes J; Mares R; Barbacid M; Recio JA. 2013. Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. PLoS One 8(6):e66933. [PubMed: 23825589]  [MGI Ref ID J:203456]

Hanna SC; Krishnan B; Bailey ST; Moschos SJ; Kuan PF; Shimamura T; Osborne LD; Siegel MB; Duncan LM; O'Brien ET 3rd; Superfine R; Miller CR; Simon MC; Wong KK; Kim WY. 2013. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123(5):2078-93. [PubMed: 23563312]  [MGI Ref ID J:201460]

Held MA; Curley DP; Dankort D; McMahon M; Muthusamy V; Bosenberg MW. 2010. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70(1):388-97. [PubMed: 20048081]  [MGI Ref ID J:155731]

Ho PC; Meeth KM; Tsui YC; Srivastava B; Bosenberg MW; Kaech SM. 2014. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res 74(12):3205-17. [PubMed: 24736544]  [MGI Ref ID J:212454]

Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU. 2012. Targeting BRAFV600E in an inducible murine model of melanoma. Am J Pathol 181(3):785-94. [PubMed: 22796458]  [MGI Ref ID J:188523]

Huillard E; Hashizume R; Phillips JJ; Griveau A; Ihrie RA; Aoki Y; Nicolaides T; Perry A; Waldman T; McMahon M; Weiss WA; Petritsch C; James CD; Rowitch DH. 2012. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 109(22):8710-5. [PubMed: 22586120]  [MGI Ref ID J:184756]

Ittmann M; Huang J; Radaelli E; Martin P; Signoretti S; Sullivan R; Simons BW; Ward JM; Robinson BD; Chu GC; Loda M; Thomas G; Borowsky A; Cardiff RD. 2013. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73(9):2718-36. [PubMed: 23610450]  [MGI Ref ID J:197036]

Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M. 2014. Diminished WNT -> beta-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 28(6):561-75. [PubMed: 24589553]  [MGI Ref ID J:209631]

Kamata T; Dankort D; Kang J; Giblett S; Pritchard CA; McMahon M; Leavitt AD. 2013. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res 11(12):1530-41. [PubMed: 24152792]  [MGI Ref ID J:206521]

Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ. 2013. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123(3):1371-81. [PubMed: 23454771]  [MGI Ref ID J:196375]

Landrette SF; Cornett JC; Ni TK; Bosenberg MW; Xu T. 2011. piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One 6(10):e26650. [PubMed: 22039523]  [MGI Ref ID J:179725]

Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L. 2014. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res 74(7):1933-44. [PubMed: 24691994]  [MGI Ref ID J:210809]

Lee EK; Lian Z; D'Andrea K; Letrero R; Sheng W; Liu S; Diehl JN; Pytel D; Barbash O; Schuchter L; Amaravaradi R; Xu X; Herlyn M; Nathanson KL; Diehl JA. 2013. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 33(22):4422-33. [PubMed: 24019069]  [MGI Ref ID J:206100]

Maertens O; Johnson B; Hollstein P; Frederick DT; Cooper ZA; Messiaen L; Bronson RT; McMahon M; Granter S; Flaherty K; Wargo JA; Marais R; Cichowski K. 2013. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3(3):338-49. [PubMed: 23171796]  [MGI Ref ID J:198252]

Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M. 2013. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest 123(12):5104-18. [PubMed: 24200692]  [MGI Ref ID J:207627]

McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T. 2014. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 111(16):E1600-9. [PubMed: 24711431]  [MGI Ref ID J:208854]

Mitra D; Luo X; Morgan A; Wang J; Hoang MP; Lo J; Guerrero CR; Lennerz JK; Mihm MC; Wargo JA; Robinson KC; Devi SP; Vanover JC; D'Orazio JA; McMahon M; Bosenberg MW; Haigis KM; Haber DA; Wang Y; Fisher DE. 2012. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-53. [PubMed: 23123854]  [MGI Ref ID J:189208]

Ni TK; Landrette SF; Bjornson RD; Bosenberg MW; Xu T. 2013. Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A 110(38):E3640-9. [PubMed: 24003131]  [MGI Ref ID J:201160]

Niault TS; Baccarini M. 2010. Targets of Raf in tumorigenesis. Carcinogenesis 31(7):1165-74. [PubMed: 20047953]  [MGI Ref ID J:161650]

Sayin VI; Ibrahim MX; Larsson E; Nilsson JA; Lindahl P; Bergo MO. 2014. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 6(221):221ra15. [PubMed: 24477002]  [MGI Ref ID J:212506]

Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA. 2014. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene 33(34):4330-9. [PubMed: 24037523]  [MGI Ref ID J:214355]

Strohecker AM; Guo JY; Karsli-Uzunbas G; Price SM; Chen GJ; Mathew R; McMahon M; White E. 2013. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 3(11):1272-85. [PubMed: 23965987]  [MGI Ref ID J:206987]

Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG. 2014. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Cancer Res 74(16):4222-9. [PubMed: 24934810]  [MGI Ref ID J:213723]

Tang N; Marshall WF; McMahon M; Metzger RJ; Martin GR. 2011. Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science 333(6040):342-5. [PubMed: 21764747]  [MGI Ref ID J:174194]

Tien AC; Tsai HH; Molofsky AV; McMahon M; Foo LC; Kaul A; Dougherty JD; Heintz N; Gutmann DH; Barres BA; Rowitch DH. 2012. Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development 139(14):2477-87. [PubMed: 22675209]  [MGI Ref ID J:185602]

Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M. 2013. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res 73(21):6448-61. [PubMed: 24019382]  [MGI Ref ID J:204513]

Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M. 2012. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72(12):3048-59. [PubMed: 22511580]  [MGI Ref ID J:189336]

Vandal G; Geiling B; Dankort D. 2014. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. PLoS One 9(1):e84745. [PubMed: 24489653]  [MGI Ref ID J:212700]

Wang J; Kobayashi T; Floc'h N; Kinkade CW; Aytes A; Dankort D; Lefebvre C; Mitrofanova A; Cardiff RD; McMahon M; Califano A; Shen MM; Abate-Shen C. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72(18):4765-76. [PubMed: 22836754]  [MGI Ref ID J:191327]

Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B. 2013. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci U S A 110(45):18226-31. [PubMed: 24145418]  [MGI Ref ID J:202916]

van der Weyden L; Adams DJ. 2013. Cancer of mice and men: old twists and new tails. J Pathol 230(1):4-16. [PubMed: 23436574]  [MGI Ref ID J:196071]

Ptentm1Hwu related

Adhikari D; Zheng W; Shen Y; Gorre N; Hamalainen T; Cooney AJ; Huhtaniemi I; Lan ZJ; Liu K. 2009. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet :. [PubMed: 19843540]  [MGI Ref ID J:155357]

Adisetiyo H; Liang M; Liao CP; Aycock-Williams A; Cohen MB; Xu S; Neamati N; Conway EM; Cheng CY; Nikitin AY; Roy-Burman P. 2013. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS One 8(7):e69484. [PubMed: 23936028]  [MGI Ref ID J:203267]

Ahmad I; Morton JP; Singh LB; Radulescu SM; Ridgway RA; Patel S; Woodgett J; Winton DJ; Taketo MM; Wu XR; Leung HY; Sansom OJ. 2010. beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene :. [PubMed: 20818428]  [MGI Ref ID J:164579]

Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY. 2011. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 108(39):16392-7. [PubMed: 21930937]  [MGI Ref ID J:177138]

Ahmad I; Singh LB; Foth M; Morris CA; Taketo MM; Wu XR; Leung HY; Sansom OJ; Iwata T. 2011. K-Ras and {beta}-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 4(4):548-55. [PubMed: 21504907]  [MGI Ref ID J:174242]

Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P. 2010. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res 70(9):3473-82. [PubMed: 20406970]  [MGI Ref ID J:159457]

Alcantara Llaguno S; Chen J; Kwon CH; Jackson EL; Li Y; Burns DK; Alvarez-Buylla A; Parada LF. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15(1):45-56. [PubMed: 19111880]  [MGI Ref ID J:143505]

Anzelon AN; Wu H; Rickert RC. 2003. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4(3):287-94. [PubMed: 12563260]  [MGI Ref ID J:83213]

Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; Lekaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C. 2013. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A 110(37):E3506-15. [PubMed: 23918374]  [MGI Ref ID J:200917]

Aytes A; Mitrofanova A; Lefebvre C; Alvarez MJ; Castillo-Martin M; Zheng T; Eastham JA; Gopalan A; Pienta KJ; Shen MM; Califano A; Abate-Shen C. 2014. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5):638-51. [PubMed: 24823640]  [MGI Ref ID J:210591]

Baena E; Shao Z; Linn DE; Glass K; Hamblen MJ; Fujiwara Y; Kim J; Nguyen M; Zhang X; Godinho FJ; Bronson RT; Mucci LA; Loda M; Yuan GC; Orkin SH; Li Z. 2013. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 27(6):683-98. [PubMed: 23512661]  [MGI Ref ID J:212219]

Berquin IM; Min Y; Wu R; Wu H; Chen YQ. 2005. Expression signature of the mouse prostate. J Biol Chem 280(43):36442-51. [PubMed: 16055444]  [MGI Ref ID J:106938]

Berquin IM; Min Y; Wu R; Wu J; Perry D; Cline JM; Thomas MJ; Thornburg T; Kulik G; Smith A; Edwards IJ; D'Agostino R; Zhang H; Wu H; Kang JX; Chen YQ. 2007. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117(7):1866-75. [PubMed: 17607361]  [MGI Ref ID J:124208]

Bian Y; Hall B; Sun ZJ; Molinolo A; Chen W; Gutkind JS; Waes CV; Kulkarni AB. 2012. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31(28):3322-32. [PubMed: 22037217]  [MGI Ref ID J:194578]

Bonaguidi MA; Wheeler MA; Shapiro JS; Stadel RP; Sun GJ; Ming GL; Song H. 2011. In vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell characteristics. Cell 145(7):1142-55. [PubMed: 21664664]  [MGI Ref ID J:173371]

Boyer A; Paquet M; Lague MN; Hermo L; Boerboom D. 2009. Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis 30(5):869-78. [PubMed: 19237610]  [MGI Ref ID J:149060]

Browne CD; Del Nagro CJ; Cato MH; Dengler HS; Rickert RC. 2009. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 31(5):749-60. [PubMed: 19896393]  [MGI Ref ID J:155314]

Bun Chan C; Liu X; Pradoldej S; Hao C; An J; Yepes M; Luo HR; Ye K. 2011. Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex. J Neurosci 31(22):8083-92. [PubMed: 21632930]  [MGI Ref ID J:173380]

Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765]  [MGI Ref ID J:193498]

Byun DS; Ahmed N; Nasser S; Shin J; Al-Obaidi S; Goel S; Corner GA; Wilson AJ; Flanagan DJ; Williams DS; Augenlicht LH; Vincan E; Mariadason JM. 2011. Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol Gastrointest Liver Physiol 301(5):G856-64. [PubMed: 21836055]  [MGI Ref ID J:178019]

Cai Z; Simons DL; Fu XY; Feng GS; Wu SM; Zhang X. 2011. Loss of shp2-mediated mitogen-activated protein kinase signaling in muller glial cells results in retinal degeneration. Mol Cell Biol 31(14):2973-83. [PubMed: 21576358]  [MGI Ref ID J:174095]

Charles RP; Silva J; Iezza G; Phillips WA; McMahon M. 2014. Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Mol Cancer Res 12(7):979-86. [PubMed: 24770869]  [MGI Ref ID J:211098]

Chen CC; Stairs DB; Boxer RB; Belka GK; Horseman ND; Alvarez JV; Chodosh LA. 2012. Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. Genes Dev 26(19):2154-68. [PubMed: 23028142]  [MGI Ref ID J:188260]

Chen J; Li Y; Yu TS; McKay RM; Burns DK; Kernie SG; Parada LF. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522-6. [PubMed: 22854781]  [MGI Ref ID J:186769]

Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME. 2010. CD95 promotes tumour growth. Nature 465(7297):492-6. [PubMed: 20505730]  [MGI Ref ID J:161953]

Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ. 2014. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74(1):15-23. [PubMed: 24322983]  [MGI Ref ID J:207907]

Chiao PJ; Ling J. 2011. Kras, Pten, NF-kappaB, and inflammation: dangerous liaisons. Cancer Discov 1(2):103-5. [PubMed: 22586351]  [MGI Ref ID J:193072]

Choi N; Zhang B; Zhang L; Ittmann M; Xin L. 2012. Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation. Cancer Cell 21(2):253-65. [PubMed: 22340597]  [MGI Ref ID J:181459]

Chow DK; Groszer M; Pribadi M; Machniki M; Carmichael ST; Liu X; Trachtenberg JT. 2009. Laminar and compartmental regulation of dendritic growth in mature cortex. Nat Neurosci 12(2):116-8. [PubMed: 19151711]  [MGI Ref ID J:145970]

Clipperton-Allen AE; Page DT. 2014. Pten haploinsufficient mice show broad brain overgrowth but selective impairments in autism-relevant behavioral tests. Hum Mol Genet 23(13):3490-505. [PubMed: 24497577]  [MGI Ref ID J:210673]

Colombo S; Champeval D; Rambow F; Larue L. 2012. Transcriptomic analysis of mouse embryonic skin cells reveals previously unreported genes expressed in melanoblasts. J Invest Dermatol 132(1):170-8. [PubMed: 21850021]  [MGI Ref ID J:180641]

Conley-LaComb MK; Huang W; Wang S; Shi D; Jung YS; Najy A; Fridman R; Bonfil RD; Cher ML; Chen YQ; Kim HR. 2012. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 180(3):1017-27. [PubMed: 22209699]  [MGI Ref ID J:181962]

Costa PM; Cardoso AL; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC. 2012. PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. Hum Mol Genet 21(23):5118-30. [PubMed: 22922228]  [MGI Ref ID J:188925]

Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR. 2009. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 77(1):103-11. [PubMed: 19281769]  [MGI Ref ID J:147066]

Cui M; Augert A; Rongione M; Conkrite K; Parazzoli S; Nikitin AY; Ingolia N; Macpherson D. 2014. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. Mol Cancer Res 12(5):654-9. [PubMed: 24482365]  [MGI Ref ID J:209151]

Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK. 2008. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68(14):5619-27. [PubMed: 18632614]  [MGI Ref ID J:139053]

Daikoku T; Jackson L; Besnard V; Whitsett J; Ellenson LH; Dey SK. 2011. Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes. Gynecol Oncol 122(2):424-9. [PubMed: 21570712]  [MGI Ref ID J:196048]

Daikoku T; Terakawa J; Hossain MM; Yoshie M; Cappelletti M; Yang P; Ellenson LH; Dey SK. 2014. Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer. Am J Pathol 184(9):2390-402. [PubMed: 25058027]  [MGI Ref ID J:213943]

Daikoku T; Tranguch S; Trofimova IN; Dinulescu DM; Jacks T; Nikitin AY; Connolly DC; Dey SK. 2006. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66(5):2527-31. [PubMed: 16510568]  [MGI Ref ID J:106703]

Dave V; Wert SE; Tanner T; Thitoff AR; Loudy DE; Whitsett JA. 2008. Conditional deletion of Pten causes bronchiolar hyperplasia. Am J Respir Cell Mol Biol 38(3):337-45. [PubMed: 17921358]  [MGI Ref ID J:146355]

Diallo-Krou E; Yu J; Colby LA; Inoki K; Wilkinson JE; Thomas DG; Giordano TJ; Koenig RJ. 2009. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150(11):5181-90. [PubMed: 19797117]  [MGI Ref ID J:158236]

Diaz-Ruiz O; Zapata A; Shan L; Zhang Y; Tomac AC; Malik N; de la Cruz F; Backman CM. 2009. Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One 4(9):e7027. [PubMed: 19750226]  [MGI Ref ID J:153622]

Dinulescu DM; Ince TA; Quade BJ; Shafer SA; Crowley D; Jacks T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63-70. [PubMed: 15619626]  [MGI Ref ID J:96296]

Dobson ME; Diallo-Krou E; Grachtchouk V; Yu J; Colby LA; Wilkinson JE; Giordano TJ; Koenig RJ. 2011. Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPAR{gamma} Fusion Protein Thyroid Carcinoma. Endocrinology 152(11):4455-65. [PubMed: 21952241]  [MGI Ref ID J:177181]

Dourdin N; Schade B; Lesurf R; Hallett M; Munn RJ; Cardiff RD; Muller WJ. 2008. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68(7):2122-31. [PubMed: 18381417]  [MGI Ref ID J:133305]

Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Muschen M. 2011. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473(7347):384-8. [PubMed: 21593872]  [MGI Ref ID J:172636]

Ellwood-Yen K; Keilhack H; Kunii K; Dolinski B; Connor Y; Hu K; Nagashima K; O'Hare E; Erkul Y; Di Bacco A; Gargano D; Shomer NH; Angagaw M; Leccese E; Andrade P; Hurd M; Shin MK; Vogt TF; Northrup A; Bobkova EV; Kasibhatla S; Bronson RT; Scott ML; Draetta G; Richon V; Kohl N; Blume-Jensen P; Andersen JN; Kraus M. 2011. PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models. Cancer Res 71(8):3052-65. [PubMed: 21493594]  [MGI Ref ID J:170965]

Fan HY; Liu Z; Cahill N; Richards JS. 2008. Targeted disruption of pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 22(9):2128-40. [PubMed: 18606860]  [MGI Ref ID J:138315]

Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; del Mar Inda M; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 109(35):14164-9. [PubMed: 22891331]  [MGI Ref ID J:188576]

Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C. 2012. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 72(17):4483-93. [PubMed: 22815528]  [MGI Ref ID J:191334]

Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T. 2014. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J Pathol 233(2):148-58. [PubMed: 24519156]  [MGI Ref ID J:210834]

Francis JC; Thomsen MK; Taketo MM; Swain A. 2013. beta-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet 9(1):e1003180. [PubMed: 23300485]  [MGI Ref ID J:195087]

Freeman D; Lesche R; Kertesz N; Wang S; Li G; Gao J; Groszer M; Martinez-Diaz H; Rozengurt N; Thomas G; Liu X; Wu H. 2006. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66(13):6492-6. [PubMed: 16818619]  [MGI Ref ID J:110567]

Frew IJ; Minola A; Georgiev S; Hitz M; Moch H; Richard S; Vortmeyer AO; Krek W. 2008. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol 28(14):4536-48. [PubMed: 18474617]  [MGI Ref ID J:137442]

Frew IJ; Thoma CR; Georgiev S; Minola A; Hitz M; Montani M; Moch H; Krek W. 2008. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27(12):1747-57. [PubMed: 18497742]  [MGI Ref ID J:137073]

Fu Y; Wey S; Wang M; Ye R; Liao CP; Roy-Burman P; Lee AS. 2008. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A 105(49):19444-9. [PubMed: 19033462]  [MGI Ref ID J:142106]

Furumoto Y; Charles N; Olivera A; Leung WH; Dillahunt S; Sargent JL; Tinsley K; Odom S; Scott E; Wilson TM; Ghoreschi K; Kneilling M; Chen M; Lee DM; Bolland S; Rivera J. 2011. PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 118(20):5466-75. [PubMed: 21926349]  [MGI Ref ID J:178784]

Garcia-Junco-Clemente P; Chow DK; Tring E; Lazaro MT; Trachtenberg JT; Golshani P. 2013. Overexpression of calcium-activated potassium channels underlies cortical dysfunction in a model of PTEN-associated autism. Proc Natl Acad Sci U S A 110(45):18297-302. [PubMed: 24145404]  [MGI Ref ID J:202919]

Geary LA; Nash KA; Adisetiyo H; Liang M; Liao CP; Jeong JH; Zandi E; Roy-Burman P. 2014. CAF-Secreted Annexin A1 Induces Prostate Cancer Cells to Gain Stem Cell-like Features. Mol Cancer Res 12(4):607-21. [PubMed: 24464914]  [MGI Ref ID J:208332]

Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL. 2011. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 360(2):329-42. [PubMed: 22015718]  [MGI Ref ID J:178714]

Goebbels S; Oltrogge JH; Kemper R; Heilmann I; Bormuth I; Wolfer S; Wichert SP; Mobius W; Liu X; Lappe-Siefke C; Rossner MJ; Groszer M; Suter U; Frahm J; Boretius S; Nave KA. 2010. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci 30(26):8953-64. [PubMed: 20592216]  [MGI Ref ID J:161841]

Goel HL; Chang C; Pursell B; Leav I; Lyle S; Xi HS; Hsieh CC; Adisetiyo H; Roy-Burman P; Coleman IM; Nelson PS; Vessella RL; Davis RJ; Plymate SR; Mercurio AM. 2012. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2(10):906-21. [PubMed: 22777769]  [MGI Ref ID J:193157]

Goertz MJ; Wu Z; Gallardo TD; Hamra FK; Castrillon DH. 2011. Foxo1 is required in mouse spermatogonial stem cells for their maintenance and the initiation of spermatogenesis. J Clin Invest 121(9):3456-66. [PubMed: 21865646]  [MGI Ref ID J:178240]

Gregorian C ; Nakashima J ; Le Belle J ; Ohab J ; Kim R ; Liu A ; Smith KB ; Groszer M ; Garcia AD ; Sofroniew MV ; Carmichael ST ; Kornblum HI ; Liu X ; Wu H. 2009. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci 29(6):1874-86. [PubMed: 19211894]  [MGI Ref ID J:146630]

Gregorian C; Nakashima J; Dry SM; Nghiemphu PL; Smith KB; Ao Y; Dang J; Lawson G; Mellinghoff IK; Mischel PS; Phelps M; Parada LF; Liu X; Sofroniew MV; Eilber FC; Wu H. 2009. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A 106(46):19479-84. [PubMed: 19846776]  [MGI Ref ID J:154673]

Groszer M; Erickson R; Scripture-Adams DD; Dougherty JD; Le Belle J; Zack JA; Geschwind DH; Liu X; Kornblum HI; Wu H. 2006. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A 103(1):111-116. [PubMed: 16373498]  [MGI Ref ID J:104566]

Groszer M; Erickson R; Scripture-Adams DD; Lesche R; Trumpp A; Zack JA; Kornblum HI; Liu X; Wu H. 2001. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186-9. [PubMed: 11691952]  [MGI Ref ID J:73255]

Gu Y; Lindner J; Kumar A; Yuan W; Magnuson MA. 2011. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes 60(3):827-37. [PubMed: 21266327]  [MGI Ref ID J:170129]

Gu Z; Wu J; Wang S; Suburu J; Chen H; Thomas MJ; Shi L; Edwards IJ; Berquin IM; Chen YQ. 2013. Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells. Carcinogenesis 34(9):1968-75. [PubMed: 23633519]  [MGI Ref ID J:200095]

Guan B; Rahmanto YS; Wu RC; Wang Y; Wang Z; Wang TL; Shih IeM. 2014. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 106(7):. [PubMed: 24899687]  [MGI Ref ID J:213493]

Guertin DA; Stevens DM; Saitoh M; Kinkel S; Crosby K; Sheen JH; Mullholland DJ; Magnuson MA; Wu H; Sabatini DM. 2009. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2):148-59. [PubMed: 19185849]  [MGI Ref ID J:144810]

Guha M; Plescia J; Leav I; Li J; Languino LR; Altieri DC. 2009. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 69(12):4954-8. [PubMed: 19470765]  [MGI Ref ID J:149666]

Guo W; Lasky JL; Chang CJ; Mosessian S; Lewis X; Xiao Y; Yeh JE; Chen JY; Iruela-Arispe ML; Varella-Garcia M; Wu H. 2008. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453(7194):529-33. [PubMed: 18463637]  [MGI Ref ID J:135172]

Guo W; Schubbert S; Chen JY; Valamehr B; Mosessian S; Shi H; Dang NH; Garcia C; Theodoro MF; Varella-Garcia M; Wu H. 2011. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A 108(4):1409-14. [PubMed: 21212363]  [MGI Ref ID J:168259]

Hand TW; Cui W; Jung YW; Sefik E; Joshi NS; Chandele A; Liu Y; Kaech SM. 2010. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A 107(38):16601-6. [PubMed: 20823247]  [MGI Ref ID J:164425]

He L; Hou X; Kanel G; Zeng N; Galicia V; Wang Y; Yang J; Wu H; Birnbaum MJ; Stiles BL. 2010. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am J Pathol 176(5):2302-8. [PubMed: 20348245]  [MGI Ref ID J:160759]

He XC; Yin T; Grindley JC; Tian Q; Sato T; Tao WA; Dirisina R; Porter-Westpfahl KS; Hembree M; Johnson T; Wiedemann LM; Barrett TA; Hood L; Wu H; Li L. 2007. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39(2):189-98. [PubMed: 17237784]  [MGI Ref ID J:118329]

Henao-Mejia J; Williams A; Goff LA; Staron M; Licona-Limon P; Kaech SM; Nakayama M; Rinn JL; Flavell RA. 2013. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity 38(5):984-97. [PubMed: 23623381]  [MGI Ref ID J:203157]

Hertzler-Schaefer K; Mathew G; Somani AK; Tholpady S; Kadakia MP; Chen Y; Spandau DF; Zhang X. 2014. Pten loss induces autocrine FGF signaling to promote skin tumorigenesis. Cell Rep 6(5):818-26. [PubMed: 24582960]  [MGI Ref ID J:211713]

Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H. 2010. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70(18):7114-24. [PubMed: 20807812]  [MGI Ref ID J:164210]

Hill R; Li Y; Tran LM; Dry S; Calvopina JH; Garcia A; Kim C; Wang Y; Donahue TR; Herschman HR; Wu H. 2012. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 11(10):2127-37. [PubMed: 22784710]  [MGI Ref ID J:208743]

Hill R; Song Y; Cardiff RD; Van Dyke T. 2005. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 65(22):10243-54. [PubMed: 16288012]  [MGI Ref ID J:103408]

Hsieh AC; Liu Y; Edlind MP; Ingolia NT; Janes MR; Sher A; Shi EY; Stumpf CR; Christensen C; Bonham MJ; Wang S; Ren P; Martin M; Jessen K; Feldman ME; Weissman JS; Shokat KM; Rommel C; Ruggero D. 2012. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485(7396):55-61. [PubMed: 22367541]  [MGI Ref ID J:183775]

Hu Z; Wang H; Lee IH; Modi S; Wang X; Du J; Mitch WE. 2010. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes 59(6):1312-20. [PubMed: 20200318]  [MGI Ref ID J:169364]

Hubner A; Mulholland DJ; Standen CL; Karasarides M; Cavanagh-Kyros J; Barrett T; Chi H; Greiner DL; Tournier C; Sawyers CL; Flavell RA; Wu H; Davis RJ. 2012. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 109(30):12046-51. [PubMed: 22753496]  [MGI Ref ID J:186492]

Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Muller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Muschen M. 2011. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208(11):2163-74. [PubMed: 21911423]  [MGI Ref ID J:178790]

Huse JT; Holland EC. 2009. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 19(1):132-43. [PubMed: 19076778]  [MGI Ref ID J:173443]

Inoue K; Rispoli J; Yang L; Macleod D; Beal MF; Klann E; Abeliovich A. 2013. Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway. PLoS Genet 9(10):e1003845. [PubMed: 24098148]  [MGI Ref ID J:202819]

Ittmann M; Huang J; Radaelli E; Martin P; Signoretti S; Sullivan R; Simons BW; Ward JM; Robinson BD; Chu GC; Loda M; Thomas G; Borowsky A; Cardiff RD. 2013. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73(9):2718-36. [PubMed: 23610450]  [MGI Ref ID J:197036]

Iwanaga K; Yang Y; Raso MG; Ma L; Hanna AE; Thilaganathan N; Moghaddam S; Evans CM; Li H; Cai WW; Sato M; Minna JD; Wu H; Creighton CJ; Demayo FJ; Wistuba II; Kurie JM. 2008. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68(4):1119-27. [PubMed: 18281487]  [MGI Ref ID J:131721]

Jagarlamudi K; Liu L; Adhikari D; Reddy P; Idahl A; Ottander U; Lundin E; Liu K. 2009. Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One 4(7):e6186. [PubMed: 19587782]  [MGI Ref ID J:151696]

Janzen DM; Rosales MA; Paik DY; Lee DS; Smith DA; Witte ON; Iruela-Arispe ML; Memarzadeh S. 2013. Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy. Cancer Res 73(15):4697-4710. [PubMed: 23744837]  [MGI Ref ID J:199569]

Jellusova J; Miletic AV; Cato MH; Lin WW; Hu Y; Bishop GA; Shlomchik MJ; Rickert RC. 2013. Context-specific BAFF-R signaling by the NF-kappaB and PI3K pathways. Cell Rep 5(4):1022-35. [PubMed: 24239354]  [MGI Ref ID J:205520]

Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM. 2013. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3(1):44-51. [PubMed: 23258246]  [MGI Ref ID J:194362]

Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ. 2008. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776-9. [PubMed: 18594509]  [MGI Ref ID J:138565]

Jiao J; Dragomir AC; Kocabayoglu P; Rahman AH; Chow A; Hashimoto D; Leboeuf M; Kraus T; Moran T; Carrasco-Avino G; Friedman SL; Merad M; Aloman C. 2014. Central role of conventional dendritic cells in regulation of bone marrow release and survival of neutrophils. J Immunol 192(7):3374-82. [PubMed: 24591364]  [MGI Ref ID J:209877]

John GB; Gallardo TD; Shirley LJ; Castrillon DH. 2008. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev Biol 321(1):197-204. [PubMed: 18601916]  [MGI Ref ID J:138697]

Joshi A; Ellenson LH. 2011. Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma. Exp Cell Res 317(11):1580-9. [PubMed: 21397598]  [MGI Ref ID J:174151]

Jun HJ; Acquaviva J; Chi D; Lessard J; Zhu H; Woolfenden S; Bronson RT; Pfannl R; White F; Housman DE; Iyer L; Whittaker CA; Boskovitz A; Raval A; Charest A. 2012. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31(25):3039-50. [PubMed: 22020333]  [MGI Ref ID J:186125]

Jun HJ; Bronson RT; Charest A. 2014. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells 32(2):338-48. [PubMed: 24115218]  [MGI Ref ID J:206766]

Kalaitzidis D; Sykes SM; Wang Z; Punt N; Tang Y; Ragu C; Sinha AU; Lane SW; Souza AL; Clish CB; Anastasiou D; Gilliland DG; Scadden DT; Guertin DA; Armstrong SA. 2012. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11(3):429-39. [PubMed: 22958934]  [MGI Ref ID J:193428]

Kang SG; Liu WH; Lu P; Jin HY; Lim HW; Shepherd J; Fremgen D; Verdin E; Oldstone MB; Qi H; Teijaro JR; Xiao C. 2013. MicroRNAs of the miR-17 approximately 92 family are critical regulators of T(FH) differentiation. Nat Immunol 14(8):849-57. [PubMed: 23812097]  [MGI Ref ID J:201798]

Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG. 2013. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. J Pathol 230(4):430-40. [PubMed: 23616343]  [MGI Ref ID J:198826]

Kenerson HL; Yeh MM; Yeung RS. 2011. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS One 6(3):e18075. [PubMed: 21479224]  [MGI Ref ID J:171445]

Khodavirdi AC; Song Z; Yang S; Zhong C; Wang S; Wu H; Pritchard C; Nelson PS; Roy-Burman P. 2006. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66(2):883-8. [PubMed: 16424021]  [MGI Ref ID J:106566]

Kim HJ; Woo HM; Ryu J; Bok J; Kim JW; Choi SB; Park MH; Park HY; Koo SK. 2013. Conditional deletion of pten leads to defects in nerve innervation and neuronal survival in inner ear development. PLoS One 8(2):e55609. [PubMed: 23393595]  [MGI Ref ID J:197212]

Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA. 2012. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res 72(22):6065-75. [PubMed: 22986743]  [MGI Ref ID J:192887]

Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA. 2009. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 5(7):e1000542. [PubMed: 19578399]  [MGI Ref ID J:151623]

Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA. 2012. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 31(3):322-32. [PubMed: 21685943]  [MGI Ref ID J:181074]

Kim TH; Franco HL; Jung SY; Qin J; Broaddus RR; Lydon JP; Jeong JW. 2010. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 29(26):3770-80. [PubMed: 20418913]  [MGI Ref ID J:162027]

Kinross KM; Montgomery KG; Kleinschmidt M; Waring P; Ivetac I; Tikoo A; Saad M; Hare L; Roh V; Mantamadiotis T; Sheppard KE; Ryland GL; Campbell IG; Gorringe KL; Christensen JG; Cullinane C; Hicks RJ; Pearson RB; Johnstone RW; McArthur GA; Phillips WA. 2012. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122(2):553-7. [PubMed: 22214849]  [MGI Ref ID J:184382]

Klein RD. 2005. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat Res 576(1-2):111-9. [PubMed: 15885713]  [MGI Ref ID J:100619]

Klezovitch O; Risk M; Coleman I; Lucas JM; Null M; True LD; Nelson PS; Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105(6):2105-10. [PubMed: 18245377]  [MGI Ref ID J:131932]

Klymiuk N; van Buerck L; Bahr A; Offers M; Kessler B; Wuensch A; Kurome M; Thormann M; Lochner K; Nagashima H; Herbach N; Wanke R; Seissler J; Wolf E. 2012. Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. Diabetes 61(6):1527-32. [PubMed: 22522620]  [MGI Ref ID J:196821]

Kurlawalla-Martinez C; Stiles B; Wang Y; Devaskar SU; Kahn BB; Wu H. 2005. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25(6):2498-510. [PubMed: 15743841]  [MGI Ref ID J:97588]

Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z. 2013. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS One 8(1):e53476. [PubMed: 23308230]  [MGI Ref ID J:195810]

Kwon CH; Zhao D; Chen J; Alcantara S; Li Y; Burns DK; Mason RP; Lee EY; Wu H; Parada LF. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68(9):3286-94. [PubMed: 18451155]  [MGI Ref ID J:134611]

Kwon OJ; Zhang L; Ittmann MM; Xin L. 2014. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A 111(5):E592-600. [PubMed: 24367088]  [MGI Ref ID J:206383]

Lague MN; Detmar J; Paquet M; Boyer A; Richards JS; Adamson SL; Boerboom D. 2010. Decidual PTEN expression is required for trophoblast invasion in the mouse. Am J Physiol Endocrinol Metab 299(6):E936-46. [PubMed: 20858757]  [MGI Ref ID J:170203]

Lague MN; Paquet M; Fan HY; Kaartinen MJ; Chu S; Jamin SP; Behringer RR; Fuller PJ; Mitchell A; Dore M; Huneault LM; Richards JS; Boerboom D. 2008. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 29(11):2062-72. [PubMed: 18687666]  [MGI Ref ID J:142150]

Langlois MJ; Roy SA; Auclair BA; Jones C; Boudreau F; Carrier JC; Rivard N; Perreault N. 2009. Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia. FASEB J 23(6):1835-44. [PubMed: 19168705]  [MGI Ref ID J:150553]

Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC. 2010. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 176(1):393-401. [PubMed: 19948822]  [MGI Ref ID J:156382]

Lee JY; Nakada D; Yilmaz OH; Tothova Z; Joseph NM; Lim MS; Gilliland DG; Morrison SJ. 2010. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 7(5):593-605. [PubMed: 21040901]  [MGI Ref ID J:167537]

Lehtinen MK; Zappaterra MW; Chen X; Yang YJ; Hill AD; Lun M; Maynard T; Gonzalez D; Kim S; Ye P; D'Ercole AJ; Wong ET; LaMantia AS; Walsh CA. 2011. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69(5):893-905. [PubMed: 21382550]  [MGI Ref ID J:174742]

Lei L; Sonabend AM; Guarnieri P; Soderquist C; Ludwig T; Rosenfeld S; Bruce JN; Canoll P. 2011. Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype. PLoS One 6(5):e20041. [PubMed: 21625383]  [MGI Ref ID J:172585]

Lesche R; Groszer M; Gao J; Wang Y; Messing A; Sun H; Liu X; Wu H. 2002. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32(2):148-9. [PubMed: 11857804]  [MGI Ref ID J:75117]

Li C; Li Y; He L; Agarwal AR; Zeng N; Cadenas E; Stiles BL. 2013. PI3K/AKT signaling regulates bioenergetics in immortalized hepatocytes. Free Radic Biol Med 60:29-40. [PubMed: 23376468]  [MGI Ref ID J:201239]

Li G; Robinson GW; Lesche R; Martinez-Diaz H; Jiang Z; Rozengurt N; Wagner KU; Wu DC; Lane TF; Liu X; Hennighausen L; Wu H. 2002. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129(17):4159-70. [PubMed: 12163417]  [MGI Ref ID J:78415]

Li W; Huang R; Chen Z; Yan LJ; Simpkins JW; Yang SH. 2014. PTEN degradation after ischemic stroke: a double-edged sword. Neuroscience 274:153-61. [PubMed: 24875179]  [MGI Ref ID J:213269]

Li Y; Jia Y; Pichavant M; Loison F; Sarraj B; Kasorn A; You J; Robson BE; Umetsu DT; Mizgerd JP; Ye K; Luo HR. 2009. Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia. Blood 113(20):4930-41. [PubMed: 19286998]  [MGI Ref ID J:148947]

Liao CP; Adisetiyo H; Liang M; Roy-Burman P. 2010. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70(18):7294-303. [PubMed: 20807814]  [MGI Ref ID J:164208]

Liao CP; Zhong C; Saribekyan G; Bading J; Park R; Conti PS; Moats R; Berns A; Shi W; Zhou Z; Nikitin AY; Roy-Burman P. 2007. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67(15):7525-33. [PubMed: 17671224]  [MGI Ref ID J:123911]

Lindberg ME; Stodden GR; King ML; MacLean JA 2nd; Mann JL; DeMayo FJ; Lydon JP; Hayashi K. 2013. Loss of CDH1 and pten accelerates cellular invasiveness and angiogenesis in the mouse uterus. Biol Reprod 89(1):8. [PubMed: 23740945]  [MGI Ref ID J:202051]

Liu K; Lu Y; Lee JK; Samara R; Willenberg R; Sears-Kraxberger I; Tedeschi A; Park KK; Jin D; Cai B; Xu B; Connolly L; Steward O; Zheng B; He Z. 2010. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci 13(9):1075-81. [PubMed: 20694004]  [MGI Ref ID J:165283]

Lu TL; Chang JL; Liang CC; You LR; Chen CM. 2007. Tumor spectrum, tumor latency and tumor incidence of the pten-deficient mice. PLoS ONE 2(11):e1237. [PubMed: 18043744]  [MGI Ref ID J:130367]

Lukacs RU; Memarzadeh S; Wu H; Witte ON. 2010. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6):682-93. [PubMed: 21112563]  [MGI Ref ID J:168487]

Macdonald FH; Yao D; Quinn JA; Greenhalgh DA. 2014. PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition. Oncogene 33(32):4132-43. [PubMed: 24037529]  [MGI Ref ID J:213043]

Magee JA; Ikenoue T; Nakada D; Lee JY; Guan KL; Morrison SJ. 2012. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11(3):415-28. [PubMed: 22958933]  [MGI Ref ID J:191342]

Maire CL; Ramkissoon S; Hayashi M; Haidar S; Ramkissoon L; DiTomaso E; Ligon KL. 2014. Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells 32(1):313-26. [PubMed: 24395742]  [MGI Ref ID J:206870]

Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K. 2011. Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition. Am J Pathol 179(1):422-35. [PubMed: 21703421]  [MGI Ref ID J:173998]

McFadden DG; Papagiannakopoulos T; Taylor-Weiner A; Stewart C; Carter SL; Cibulskis K; Bhutkar A; McKenna A; Dooley A; Vernon A; Sougnez C; Malstrom S; Heimann M; Park J; Chen F; Farago AF; Dayton T; Shefler E; Gabriel S; Getz G; Jacks T. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156(6):1298-311. [PubMed: 24630729]  [MGI Ref ID J:211996]

McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T. 2014. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 111(16):E1600-9. [PubMed: 24711431]  [MGI Ref ID J:208854]

McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y. 2012. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci 32(45):15704-14. [PubMed: 23136410]  [MGI Ref ID J:192244]

Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; Lopez-Garcia MA; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ. 2014. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol 233(2):124-37. [PubMed: 24615332]  [MGI Ref ID J:210989]

Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ. 2013. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Cancer Res 73(23):7034-42. [PubMed: 24154871]  [MGI Ref ID J:206519]

Michaud J; Im DS; Hla T. 2010. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 184(3):1475-83. [PubMed: 20042570]  [MGI Ref ID J:159530]

Miletic AV; Anzelon-Mills AN; Mills DM; Omori SA; Pedersen IM; Shin DM; Ravetch JV; Bolland S; Morse HC 3rd; Rickert RC. 2010. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 207(11):2407-20. [PubMed: 20956547]  [MGI Ref ID J:166155]

Ming M; Feng L; Shea CR; Soltani K; Zhao B; Han W; Smart RC; Trempus CS; He YY. 2011. PTEN Positively Regulates UVB-Induced DNA Damage Repair. Cancer Res 71(15):5287-95. [PubMed: 21771908]  [MGI Ref ID J:174190]

Ming M; Shea CR; Feng L; Soltani K; He YY. 2011. UVA induces lesions resembling seborrheic keratoses in mice with keratinocyte-specific PTEN downregulation. J Invest Dermatol 131(7):1583-6. [PubMed: 21390050]  [MGI Ref ID J:182077]

Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergada L; Maiques O; Matias-Guiu X; Dolcet X. 2013. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. Dis Model Mech 6(3):710-20. [PubMed: 23471917]  [MGI Ref ID J:196368]

Mondal S; Ghosh-Roy S; Loison F; Li Y; Jia Y; Harris C; Williams DA; Luo HR. 2011. PTEN negatively regulates engulfment of apoptotic cells by modulating activation of Rac GTPase. J Immunol 187(11):5783-94. [PubMed: 22043008]  [MGI Ref ID J:179722]

Mondal S; Subramanian KK; Sakai J; Bajrami B; Luo HR. 2012. Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion. Mol Biol Cell 23(7):1219-30. [PubMed: 22323291]  [MGI Ref ID J:196999]

Moon BC; Hernandez-Ono A; Stiles B; Wu H; Ginsberg HN. 2012. Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol 32(2):236-46. [PubMed: 22155452]  [MGI Ref ID J:195966]

Mulholland DJ; Kobayashi N; Ruscetti M; Zhi A; Tran LM; Huang J; Gleave M; Wu H. 2012. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72(7):1878-89. [PubMed: 22350410]  [MGI Ref ID J:184935]

Mulholland DJ; Tran LM; Li Y; Cai H; Morim A; Wang S; Plaisier S; Garraway IP; Huang J; Graeber TG; Wu H. 2011. Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell 19(6):792-804. [PubMed: 21620777]  [MGI Ref ID J:172730]

Mulholland DJ; Xin L; Morim A; Lawson D; Witte O; Wu H. 2009. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69(22):8555-62. [PubMed: 19887604]  [MGI Ref ID J:154444]

Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS. 2011. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-36. [PubMed: 21423204]  [MGI Ref ID J:174632]

Mullany LK; Liu Z; Wong KK; Deneke V; Ren YA; Herron A; Richards JS. 2014. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol 28(1):127-37. [PubMed: 24264574]  [MGI Ref ID J:211895]

Nahar R; Ramezani-Rad P; Mossner M; Duy C; Cerchietti L; Geng H; Dovat S; Jumaa H; Ye BH; Melnick A; Muschen M. 2011. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood 118(15):4174-8. [PubMed: 21856866]  [MGI Ref ID J:178400]

Napoli E; Ross-Inta C; Wong S; Hung C; Fujisawa Y; Sakaguchi D; Angelastro J; Omanska-Klusek A; Schoenfeld R; Giulivi C. 2012. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One 7(8):e42504. [PubMed: 22900024]  [MGI Ref ID J:189934]

Narayanan NK; Nargi D; Randolph C; Narayanan BA. 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1-8. [PubMed: 19326431]  [MGI Ref ID J:151360]

Omori SA; Cato MH; Anzelon-Mills A; Puri KD; Shapiro-Shelef M; Calame K; Rickert RC. 2006. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25(4):545-57. [PubMed: 17000121]  [MGI Ref ID J:114881]

Parapuram SK; Shi-wen X; Elliott C; Welch ID; Jones H; Baron M; Denton CP; Abraham DJ; Leask A. 2011. Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol 131(10):1996-2003. [PubMed: 21654839]  [MGI Ref ID J:182199]

Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY. 2013. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest 123(3):1157-75. [PubMed: 23434594]  [MGI Ref ID J:196384]

Peng C; Chen Y; Yang Z; Zhang H; Osterby L; Rosmarin AG; Li S. 2010. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115(3):626-35. [PubMed: 19965668]  [MGI Ref ID J:156831]

Perets R; Wyant GA; Muto KW; Bijron JG; Poole BB; Chin KT; Chen JY; Ohman AW; Stepule CD; Kwak S; Karst AM; Hirsch MS; Setlur SR; Crum CP; Dinulescu DM; Drapkin R. 2013. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6):751-65. [PubMed: 24332043]  [MGI Ref ID J:207621]

Perry JM; He XC; Sugimura R; Grindley JC; Haug JS; Ding S; Li L. 2011. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 25(18):1928-42. [PubMed: 21890648]  [MGI Ref ID J:176204]

Powers SE; Mandal M; Matsuda S; Miletic AV; Cato MH; Tanaka A; Rickert RC; Koyasu S; Clark MR. 2012. Subnuclear cyclin D3 compartments and the coordinated regulation of proliferation and immunoglobulin variable gene repression. J Exp Med 209(12):2199-213. [PubMed: 23109711]  [MGI Ref ID J:190888]

Puig I; Champeval D; De Santa Barbara P; Jaubert F; Lyonnet S; Larue L. 2009. Deletion of Pten in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J Clin Invest 119(12):3586-96. [PubMed: 19884655]  [MGI Ref ID J:155110]

Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C. 2009. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6):675-80. [PubMed: 19261747]  [MGI Ref ID J:146760]

Qian J; Ling S; Castillo AC; Long B; Birnbaum Y; Ye Y. 2012. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. Am J Physiol Heart Circ Physiol 302(9):H1806-17. [PubMed: 22367504]  [MGI Ref ID J:186577]

Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY. 2013. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature 493(7431):236-40. [PubMed: 23201680]  [MGI Ref ID J:194187]

Reddy P; Liu L; Adhikari D; Jagarlamudi K; Rajareddy S; Shen Y; Du C; Tang W; Hamalainen T; Peng SL; Lan ZJ; Cooney AJ; Huhtaniemi I; Liu K. 2008. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319(5863):611-3. [PubMed: 18239123]  [MGI Ref ID J:131827]

Richards JS; Fan HY; Liu Z; Tsoi M; Lague MN; Boyer A; Boerboom D. 2012. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 31(12):1504-20. [PubMed: 21860425]  [MGI Ref ID J:186144]

Ricke EA; Williams K; Lee YF; Couto S; Wang Y; Hayward SW; Cunha GR; Ricke WA. 2012. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis 33(7):1391-8. [PubMed: 22535887]  [MGI Ref ID J:190775]

Rico C; Lague MN; Lefevre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau ME; Boerboom D. 2012. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. Carcinogenesis 33(11):2283-92. [PubMed: 22871496]  [MGI Ref ID J:193228]

Rommel PC; Bosque D; Gitlin AD; Croft GF; Heintz N; Casellas R; Nussenzweig MC; Kriaucionis S; Robbiani DF. 2013. Fate mapping for activation-induced cytidine deaminase (AID) marks non-lymphoid cells during mouse development. PLoS One 8(7):e69208. [PubMed: 23861962]  [MGI Ref ID J:204283]

Ruan H; Li J; Ren S; Gao J; Li G; Kim R; Wu H; Wang Y. 2009. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J Mol Cell Cardiol 46(2):193-200. [PubMed: 19038262]  [MGI Ref ID J:149180]

Sakagami K; Chen B; Nusinowitz S; Wu H; Yang XJ. 2012. PTEN regulates retinal interneuron morphogenesis and synaptic layer formation. Mol Cell Neurosci 49(2):171-83. [PubMed: 22155156]  [MGI Ref ID J:191532]

Sarraj B; Massberg S; Li Y; Kasorn A; Subramanian K; Loison F; Silberstein LE; von Andrian U; Luo HR. 2009. Myeloid-specific deletion of tumor suppressor PTEN augments neutrophil transendothelial migration during inflammation. J Immunol 182(11):7190-200. [PubMed: 19454716]  [MGI Ref ID J:148853]

Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ. 2009. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 284(28):19018-26. [PubMed: 19435886]  [MGI Ref ID J:207672]

Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ. 2014. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111(17):6395-400. [PubMed: 24737887]  [MGI Ref ID J:208835]

Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA. 2014. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene 33(34):4330-9. [PubMed: 24037523]  [MGI Ref ID J:214355]

Sengupta P; Basu S; Soni S; Pandey A; Roy B; Oh MS; Chin KT; Paraskar AS; Sarangi S; Connor Y; Sabbisetti VS; Kopparam J; Kulkarni A; Muto K; Amarasiriwardena C; Jayawardene I; Lupoli N; Dinulescu DM; Bonventre JV; Mashelkar RA; Sengupta S. 2012. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 109(28):11294-9. [PubMed: 22733767]  [MGI Ref ID J:186400]

Signer RA; Magee JA; Salic A; Morrison SJ. 2014. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 509(7498):49-54. [PubMed: 24670665]  [MGI Ref ID J:210464]

Snaidero N; Mobius W; Czopka T; Hekking LH; Mathisen C; Verkleij D; Goebbels S; Edgar J; Merkler D; Lyons DA; Nave KA; Simons M. 2014. Myelin Membrane Wrapping of CNS Axons by PI(3,4,5)P3-Dependent Polarized Growth at the Inner Tongue. Cell 156(1-2):277-90. [PubMed: 24439382]  [MGI Ref ID J:205563]

Sonabend AM; Bansal M; Guarnieri P; Lei L; Amendolara B; Soderquist C; Leung R; Yun J; Kennedy B; Sisti J; Bruce S; Bruce R; Shakya R; Ludwig T; Rosenfeld S; Sims PA; Bruce JN; Califano A; Canoll P. 2014. The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. Cancer Res 74(5):1440-51. [PubMed: 24390738]  [MGI Ref ID J:208162]

Song H; Yao E; Lin C; Gacayan R; Chen MH; Chuang PT. 2012. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A 109(43):17531-6. [PubMed: 23047698]  [MGI Ref ID J:190366]

Squarize CH; Castilho RM; Gutkind JS. 2008. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 68(17):7066-72. [PubMed: 18757421]  [MGI Ref ID J:138927]

Srinivasan L; Sasaki Y; Calado DP; Zhang B; Paik JH; DePinho RA; Kutok JL; Kearney JF; Otipoby KL; Rajewsky K. 2009. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139(3):573-86. [PubMed: 19879843]  [MGI Ref ID J:157297]

Stanger BZ; Stiles B; Lauwers GY; Bardeesy N; Mendoza M; Wang Y; Greenwood A; Cheng KH; McLaughlin M; Brown D; Depinho RA; Wu H; Melton DA; Dor Y. 2005. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185-95. [PubMed: 16169464]  [MGI Ref ID J:102226]

Stiles B; Wang Y; Stahl A; Bassilian S; Lee WP; Kim YJ; Sherwin R; Devaskar S; Lesche R; Magnuson MA; Wu H. 2004. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101(7):2082-7. [PubMed: 14769918]  [MGI Ref ID J:88441]

Stiles BL; Kuralwalla-Martinez C; Guo W; Gregorian C; Wang Y; Tian J; Magnuson MA; Wu H. 2006. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26(7):2772-81. [PubMed: 16537919]  [MGI Ref ID J:106937]

Subramanian KK; Jia Y; Zhu D; Simms BT; Jo H; Hattori H; You J; Mizgerd JP; Luo HR. 2007. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109(9):4028-37. [PubMed: 17202315]  [MGI Ref ID J:145331]

Sun C; Zhao J; Jin Y; Hou C; Zong W; Lu T; Li H; Gao J. 2014. PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice. Neuroreport 25(3):177-83. [PubMed: 24481416]  [MGI Ref ID J:206951]

Sun X; Jackson L; Dey SK; Daikoku T. 2009. In pursuit of leucine-rich repeat-containing G protein-coupled receptor-5 regulation and function in the uterus. Endocrinology 150(11):5065-73. [PubMed: 19797400]  [MGI Ref ID J:157315]

Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB. 2012. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 18(19):5304-13. [PubMed: 22859719]  [MGI Ref ID J:194652]

Sun ZJ; Zhang L; Zhang W; Hall B; Bian Y; Kulkarni AB. 2013. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model. PLoS One 8(10):e74888. [PubMed: 24124460]  [MGI Ref ID J:209026]

Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD. 2011. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol 179(1):502-12. [PubMed: 21703427]  [MGI Ref ID J:173997]

Tandon P; Gallo CA; Khatri S; Barger JF; Yepiskoposyan H; Plas DR. 2011. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci U S A 108(6):2361-5. [PubMed: 21262837]  [MGI Ref ID J:169097]

Tang S; Moore ML; Grayson JM; Dubey P. 2012. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 72(8):1975-85. [PubMed: 22374980]  [MGI Ref ID J:185631]

Tanwar PS; Commandeur AE; Zhang L; Taketo MM; Teixeira JM. 2012. The Mullerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained beta-catenin signaling. Carcinogenesis 33(12):2351-61. [PubMed: 22962306]  [MGI Ref ID J:193300]

Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM. 2012. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1. PLoS Genet 8(8):e1002906. [PubMed: 22916036]  [MGI Ref ID J:188124]

Tanwar PS; Kaneko-Tarui T; Zhang L; Teixeira JM. 2012. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. Hum Mol Genet 21(20):4394-405. [PubMed: 22791749]  [MGI Ref ID J:187754]

Tanwar PS; Mohapatra G; Chiang S; Engler DA; Zhang L; Kaneko-Tarui T; Ohguchi Y; Birrer MJ; Teixeira JM. 2014. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis 35(3):546-53. [PubMed: 24170201]  [MGI Ref ID J:206514]

Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM. 2011. Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/beta-Catenin and PTEN. PLoS One 6(6):e20715. [PubMed: 21695255]  [MGI Ref ID J:174289]

Tesio M; Oser GM; Baccelli I; Blanco-Bose W; Wu H; Gothert JR; Kogan SC; Trumpp A. 2013. Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J Exp Med 210(11):2337-49. [PubMed: 24127490]  [MGI Ref ID J:206536]

Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Moller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A. 2010. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 70(3):979-87. [PubMed: 20103652]  [MGI Ref ID J:156856]

Tien JC; Liu Z; Liao L; Wang F; Xu Y; Wu YL; Zhou N; Ittmann M; Xu J. 2013. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res 73(13):3997-4008. [PubMed: 23650284]  [MGI Ref ID J:199012]

Ting MC; Liao CP; Yan C; Jia L; Groshen S; Frenkel B; Roy-Burman P; Coetzee GA; Maxson R. 2012. An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Dis Model Mech 5(3):366-74. [PubMed: 22279083]  [MGI Ref ID J:181487]

Tiozzo C; Carraro G; Al Alam D; Baptista S; Danopoulos S; Li A; Lavarreda-Pearce M; Li C; De Langhe S; Chan B; Borok Z; Bellusci S; Minoo P. 2012. Mesodermal Pten inactivation leads to alveolar capillary dysplasia- like phenotype. J Clin Invest 122(11):3862-72. [PubMed: 23023706]  [MGI Ref ID J:192736]

Tiozzo C; Danopoulos S; Lavarreda-Pearce M; Baptista S; Varimezova R; Al Alam D; Warburton D; Rehan V; De Langhe S; Di Cristofano A; Bellusci S; Minoo P. 2012. Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain-dependent manner. Endocr Relat Cancer 19(2):111-22. [PubMed: 22167068]  [MGI Ref ID J:197590]

Tiozzo C; De Langhe S; Yu M; Londhe VA; Carraro G; Li M; Li C; Xing Y; Anderson S; Borok Z; Bellusci S; Minoo P. 2009. Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury. Am J Respir Crit Care Med 180(8):701-12. [PubMed: 19574443]  [MGI Ref ID J:167962]

Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM. 2011. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474(7351):403-6. [PubMed: 21572435]  [MGI Ref ID J:172653]

Vivanco I; Rohle D; Versele M; Iwanami A; Kuga D; Oldrini B; Tanaka K; Dang J; Kubek S; Palaskas N; Hsueh T; Evans M; Mulholland D; Wolle D; Rajasekaran S; Rajasekaran A; Liau LM; Cloughesy TF; Dikic I; Brennan C; Wu H; Mischel PS; Perera T; Mellinghoff IK. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 107(14):6459-64. [PubMed: 20308550]  [MGI Ref ID J:159321]

Wang J; Kobayashi T; Floc'h N; Kinkade CW; Aytes A; Dankort D; Lefebvre C; Mitrofanova A; Cardiff RD; McMahon M; Califano A; Shen MM; Abate-Shen C. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72(18):4765-76. [PubMed: 22836754]  [MGI Ref ID J:191327]

Wang L; Liu Y; Yan Lu S; Nguyen KT; Schroer SA; Suzuki A; Mak TW; Gaisano H; Woo M. 2010. Deletion of Pten in pancreatic ss-cells protects against deficient ss-cell mass and function in mouse models of type 2 diabetes. Diabetes 59(12):3117-26. [PubMed: 20852026]  [MGI Ref ID J:170206]

Wang L; Opland D; Tsai S; Luk CT; Schroer SA; Allison MB; Elia AJ; Furlonger C; Suzuki A; Paige CJ; Mak TW; Winer DA; Myers MG Jr; Woo M. 2014. Pten deletion in RIP-Cre neurons protects against type 2 diabetes by activating the anti-inflammatory reflex. Nat Med 20(5):484-92. [PubMed: 24747746]  [MGI Ref ID J:213238]

Wang Q; Li SH; Wang H; Xiao Y; Sahin O; Brady SW; Li P; Ge H; Jaffee EM; Muller WJ; Hortobagyi GN; Yu D. 2012. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 72(17):4417-28. [PubMed: 22773664]  [MGI Ref ID J:191018]

Wang Q; Von T; Bronson R; Ruan M; Mu W; Huang A; Maira SM; Zhao JJ. 2013. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev 27(14):1568-80. [PubMed: 23873941]  [MGI Ref ID J:199362]

Wang S; Gao J; Lei Q; Rozengurt N; Pritchard C; Jiao J; Thomas GV; Li G; Roy-Burman P; Nelson PS; Liu X; Wu H. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4(3):209-21. [PubMed: 14522255]  [MGI Ref ID J:93902]

Wang S; Garcia AJ; Wu M; Lawson DA; Witte ON; Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103(5):1480-5. [PubMed: 16432235]  [MGI Ref ID J:105995]

Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ. 2012. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 33(2):404-12. [PubMed: 22159221]  [MGI Ref ID J:181111]

Wang X; Kruithof-de Julio M; Economides KD; Walker D; Yu H; Halili MV; Hu YP; Price SM; Abate-Shen C; Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263):495-500. [PubMed: 19741607]  [MGI Ref ID J:153425]

Wang ZA; Mitrofanova A; Bergren SK; Abate-Shen C; Cardiff RD; Califano A; Shen MM. 2013. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 15(3):274-83. [PubMed: 23434823]  [MGI Ref ID J:195200]

Weng Z; Li D; Zhang L; Chen J; Ruan C; Chen G; Gartner TK; Liu J. 2010. PTEN regulates collagen-induced platelet activation. Blood 116(14):2579-81. [PubMed: 20554973]  [MGI Ref ID J:165893]

Wey S; Luo B; Tseng CC; Ni M; Zhou H; Fu Y; Bhojwani D; Carroll WL; Lee AS. 2012. Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood 119(3):817-25. [PubMed: 21937694]  [MGI Ref ID J:181587]

White AC; Khuu JK; Dang CY; Hu J; Tran KV; Liu A; Gomez S; Zhang Z; Yi R; Scumpia P; Grigorian M; Lowry WE. 2014. Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat Cell Biol 16(1):99-107. [PubMed: 24335650]  [MGI Ref ID J:208368]

Woolfenden S; Zhu H; Charest A. 2009. A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis 47(10):659-666. [PubMed: 19603508]  [MGI Ref ID J:153565]

Xiao C; Srinivasan L; Calado DP; Patterson HC; Zhang B; Wang J; Henderson JM; Kutok JL; Rajewsky K. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405-14. [PubMed: 18327259]  [MGI Ref ID J:133215]

Xing Y; Li C; Hu L; Tiozzo C; Li M; Chai Y; Bellusci S; Anderson S; Minoo P. 2008. Mechanisms of TGFbeta inhibition of LUNG endodermal morphogenesis: the role of TbetaRII, Smads, Nkx2.1 and Pten. Dev Biol 320(2):340-50. [PubMed: 18602626]  [MGI Ref ID J:138200]

Xing Y; Li C; Li A; Sridurongrit S; Tiozzo C; Bellusci S; Borok Z; Kaartinen V; Minoo P. 2010. Signaling via Alk5 controls the ontogeny of lung Clara cells. Development 137(5):825-33. [PubMed: 20147383]  [MGI Ref ID J:157922]

Xu X; Ehdaie B; Ohara N; Yoshino T; Deng CX. 2010. Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 29(5):674-86. [PubMed: 19901970]  [MGI Ref ID J:157020]

Xu X; Kobayashi S; Qiao W; Li C; Xiao C; Radaeva S; Stiles B; Wang RH; Ohara N; Yoshino T; LeRoith D; Torbenson MS; Gores GJ; Wu H; Gao B; Deng CX. 2006. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116(7):1843-52. [PubMed: 16767220]  [MGI Ref ID J:111718]

Yang Y; Iwanaga K; Raso MG; Wislez M; Hanna AE; Wieder ED; Molldrem JJ; Wistuba II; Powis G; Demayo FJ; Kim CF; Kurie JM. 2008. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3(5):e2220. [PubMed: 18493606]  [MGI Ref ID J:136369]

Yang ZF; Zhang H; Ma L; Peng C; Chen Y; Wang J; Green MR; Li S; Rosmarin AG. 2013. GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2. Proc Natl Acad Sci U S A 110(6):2312-7. [PubMed: 23345428]  [MGI Ref ID J:194335]

Yao D; Alexander CL; Quinn JA; Chan WC; Wu H; Greenhalgh DA. 2008. Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci 121(Pt 10):1758-69. [PubMed: 18445683]  [MGI Ref ID J:138532]

Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA. 2006. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 66(3):1302-12. [PubMed: 16452183]  [MGI Ref ID J:106683]

Yeh ES; Belka GK; Vernon AE; Chen CC; Jung JJ; Chodosh LA. 2013. Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten. Proc Natl Acad Sci U S A 110(15):6103-8. [PubMed: 23520049]  [MGI Ref ID J:196198]

Yilmaz OH; Valdez R; Theisen BK; Guo W; Ferguson DO; Wu H; Morrison SJ. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475-82. [PubMed: 16598206]  [MGI Ref ID J:109085]

Yoo LI; Liu DW; Le Vu S; Bronson RT; Wu H; Yuan J. 2006. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 66(4):1929-39. [PubMed: 16488991]  [MGI Ref ID J:106662]

Yoshioka T; Otero J; Chen Y; Kim YM; Koutcher JA; Satagopan J; Reuter V; Carver B; de Stanchina E; Enomoto K; Greenberg NM; Scardino PT; Scher HI; Sawyers CL; Giancotti FG. 2013. beta4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest :. [PubMed: 23348745]  [MGI Ref ID J:194482]

Yu M; Trobridge P; Wang Y; Kanngurn S; Morris SM; Knoblaugh S; Grady WM. 2014. Inactivation of TGF-beta signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene 33(12):1538-47. [PubMed: 23604118]  [MGI Ref ID J:212371]

Yue Q; Groszer M; Gil JS; Berk AJ; Messing A; Wu H; Liu X. 2005. PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132(14):3281-91. [PubMed: 15944184]  [MGI Ref ID J:100428]

Zeiser R; Leveson-Gower DB; Zambricki EA; Kambham N; Beilhack A; Loh J; Hou JZ; Negrin RS. 2008. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111(1):453-62. [PubMed: 17967941]  [MGI Ref ID J:130295]

Zhang B; Chen H; Zhang L; Dakhova O; Zhang Y; Lewis MT; Creighton CJ; Ittmann MM; Xin L. 2014. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene 33(24):3099-108. [PubMed: 23851498]  [MGI Ref ID J:212580]

Zhang J; Grindley JC; Yin T; Jayasinghe S; He XC; Ross JT; Haug JS; Rupp D; Porter-Westpfahl KS; Wiedemann LM; Wu H; Li L. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518-22. [PubMed: 16633340]  [MGI Ref ID J:109084]

Zhang L; Sun ZJ; Bian Y; Kulkarni AB. 2013. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett 331(2):230-8. [PubMed: 23340180]  [MGI Ref ID J:194341]

Zhang Q; Liu S; Ge D; Zhang Q; Xue Y; Xiong Z; Abdel-Mageed AB; Myers L; Hill SM; Rowan BG; Sartor O; Melamed J; Chen Z; You Z. 2012. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res 72(10):2589-99. [PubMed: 22461511]  [MGI Ref ID J:189341]

Zhang W; Zhu J; Efferson CL; Ware C; Tammam J; Angagaw M; Laskey J; Bettano KA; Kasibhatla S; Reilly JF; Sur C; Majumder PK. 2009. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 69(18):7466-72. [PubMed: 19738074]  [MGI Ref ID J:152681]

Zheng W; Gorre N; Shen Y; Noda T; Ogawa W; Lundin E; Liu K. 2010. Maternal phosphatidylinositol 3-kinase signalling is crucial for embryonic genome activation and preimplantation embryogenesis. EMBO Rep 11(11):890-5. [PubMed: 20930845]  [MGI Ref ID J:165798]

Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P. 2006. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 66(4):2188-94. [PubMed: 16489020]  [MGI Ref ID J:106650]

Zhong J; Ding L; Bohrer LR; Pan Y; Liu P; Zhang J; Sebo TJ; Karnes RJ; Tindall DJ; van Deursen J; Huang H. 2014. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res 74(6):1870-80. [PubMed: 24480624]  [MGI Ref ID J:208327]

Zhu D; Hattori H; Jo H; Jia Y; Subramanian KK; Loison F; You J; Le Y; Honczarenko M; Silberstein L; Luo HR. 2006. Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proc Natl Acad Sci U S A 103(40):14836-41. [PubMed: 16988010]  [MGI Ref ID J:114699]

Zhu H; Acquaviva J; Ramachandran P; Boskovitz A; Woolfenden S; Pfannl R; Bronson RT; Chen JW; Weissleder R; Housman DE; Charest A. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 106(8):2712-6. [PubMed: 19196966]  [MGI Ref ID J:146494]

Zhu HH; Ji K; Alderson N; He Z; Li S; Liu W; Zhang DE; Li L; Feng GS. 2011. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood 117(20):5350-61. [PubMed: 21450902]  [MGI Ref ID J:177959]

Zou Y; Niu W; Qin S; Downes M; Burns DK; Zhang CL. 2012. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche. Mol Cell Biol 32(23):4811-20. [PubMed: 23028043]  [MGI Ref ID J:192734]

Tg(Tyr-cre/ERT2)13Bos related

Bosenberg M; Muthusamy V; Curley DP; Wang Z; Hobbs C; Nelson B; Nogueira C; Horner JW 2nd; Depinho R; Chin L. 2006. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44(5):262-7. [PubMed: 16676322]  [MGI Ref ID J:110143]

Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765]  [MGI Ref ID J:193498]

Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M. 2011. beta-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 20(6):741-54. [PubMed: 22172720]  [MGI Ref ID J:178598]

Gonzalez-Sanchez E; Martin-Caballero J; Flores JM; Hernandez-Losa J; Cortes J; Mares R; Barbacid M; Recio JA. 2013. Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. PLoS One 8(6):e66933. [PubMed: 23825589]  [MGI Ref ID J:203456]

Hanna SC; Krishnan B; Bailey ST; Moschos SJ; Kuan PF; Shimamura T; Osborne LD; Siegel MB; Duncan LM; O'Brien ET 3rd; Superfine R; Miller CR; Simon MC; Wong KK; Kim WY. 2013. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123(5):2078-93. [PubMed: 23563312]  [MGI Ref ID J:201460]

Hari L; Miescher I; Shakhova O; Suter U; Chin L; Taketo M; Richardson WD; Kessaris N; Sommer L. 2012. Temporal control of neural crest lineage generation by Wnt/beta-catenin signaling. Development 139(12):2107-17. [PubMed: 22573620]  [MGI Ref ID J:185553]

Harris ML; Buac K; Shakhova O; Hakami RM; Wegner M; Sommer L; Pavan WJ. 2013. A dual role for SOX10 in the maintenance of the postnatal melanocyte lineage and the differentiation of melanocyte stem cell progenitors. PLoS Genet 9(7):e1003644. [PubMed: 23935512]  [MGI Ref ID J:213046]

Held MA; Curley DP; Dankort D; McMahon M; Muthusamy V; Bosenberg MW. 2010. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70(1):388-97. [PubMed: 20048081]  [MGI Ref ID J:155731]

Ho PC; Meeth KM; Tsui YC; Srivastava B; Bosenberg MW; Kaech SM. 2014. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res 74(12):3205-17. [PubMed: 24736544]  [MGI Ref ID J:212454]

Karreth FA; Tay Y; Perna D; Ala U; Tan SM; Rust AG; Denicola G; Webster KA; Weiss D; Perez-Mancera PA; Krauthammer M; Halaban R; Provero P; Adams DJ; Tuveson DA; Pandolfi PP. 2011. In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell 147(2):382-95. [PubMed: 22000016]  [MGI Ref ID J:177503]

Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ. 2013. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123(3):1371-81. [PubMed: 23454771]  [MGI Ref ID J:196375]

Landrette SF; Cornett JC; Ni TK; Bosenberg MW; Xu T. 2011. piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One 6(10):e26650. [PubMed: 22039523]  [MGI Ref ID J:179725]

Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L. 2014. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res 74(7):1933-44. [PubMed: 24691994]  [MGI Ref ID J:210809]

Lee EK; Lian Z; D'Andrea K; Letrero R; Sheng W; Liu S; Diehl JN; Pytel D; Barbash O; Schuchter L; Amaravaradi R; Xu X; Herlyn M; Nathanson KL; Diehl JA. 2013. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 33(22):4422-33. [PubMed: 24019069]  [MGI Ref ID J:206100]

Levy C; Khaled M; Robinson KC; Veguilla RA; Chen PH; Yokoyama S; Makino E; Lu J; Larue L; Beermann F; Chin L; Bosenberg M; Song JS; Fisher DE. 2010. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 141(6):994-1005. [PubMed: 20550935]  [MGI Ref ID J:167944]

Liu W; Monahan KB; Pfefferle AD; Shimamura T; Sorrentino J; Chan KT; Roadcap DW; Ollila DW; Thomas NE; Castrillon DH; Miller CR; Perou CM; Wong KK; Bear JE; Sharpless NE. 2012. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21(6):751-64. [PubMed: 22698401]  [MGI Ref ID J:189285]

Maertens O; Johnson B; Hollstein P; Frederick DT; Cooper ZA; Messiaen L; Bronson RT; McMahon M; Granter S; Flaherty K; Wargo JA; Marais R; Cichowski K. 2013. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3(3):338-49. [PubMed: 23171796]  [MGI Ref ID J:198252]

Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M. 2013. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest 123(12):5104-18. [PubMed: 24200692]  [MGI Ref ID J:207627]

Mitra D; Luo X; Morgan A; Wang J; Hoang MP; Lo J; Guerrero CR; Lennerz JK; Mihm MC; Wargo JA; Robinson KC; Devi SP; Vanover JC; D'Orazio JA; McMahon M; Bosenberg MW; Haigis KM; Haber DA; Wang Y; Fisher DE. 2012. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-53. [PubMed: 23123854]  [MGI Ref ID J:189208]

Monahan KB; Rozenberg GI; Krishnamurthy J; Johnson SM; Liu W; Bradford MK; Horner J; Depinho RA; Sharpless NE. 2010. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene :. [PubMed: 20697345]  [MGI Ref ID J:164588]

Ni TK; Landrette SF; Bjornson RD; Bosenberg MW; Xu T. 2013. Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A 110(38):E3640-9. [PubMed: 24003131]  [MGI Ref ID J:201160]

Rabbani P; Takeo M; Chou W; Myung P; Bosenberg M; Chin L; Taketo MM; Ito M. 2011. Coordinated activation of wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 145(6):941-55. [PubMed: 21663796]  [MGI Ref ID J:173080]

Shah M; Bhoumik A; Goel V; Dewing A; Breitwieser W; Kluger H; Krajewski S; Krajewska M; Dehart J; Lau E; Kallenberg DM; Jeong H; Eroshkin A; Bennett DC; Chin L; Bosenberg M; Jones N; Ronai ZA. 2010. A Role for ATF2 in Regulating MITF and Melanoma Development. PLoS Genet 6(12):e1001258. [PubMed: 21203491]  [MGI Ref ID J:167512]

Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L. 2012. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14(8):882-90. [PubMed: 22772081]  [MGI Ref ID J:193443]

Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B. 2013. Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc Natl Acad Sci U S A 110(45):18226-31. [PubMed: 24145418]  [MGI Ref ID J:202916]

van der Weyden L; Adams DJ. 2013. Cancer of mice and men: old twists and new tails. J Pathol 230(1):4-16. [PubMed: 23436574]  [MGI Ref ID J:196071]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           FGB27

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice can be bred as hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and heterozygous for the floxed Ptentm1Hwu allele. 25% of mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele will develop melanomas with an onset of 2 to 12 months of age.
Mating System
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHeterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
$232.00Female or MaleHeterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier  
Individual Mouse $232.00Female or MaleHeterozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
$232.00Female or MaleHomozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
Price per Pair (US dollars $)Pair Genotype
$464.00Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier  
$464.00Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHeterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
$301.60Female or MaleHeterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier  
Individual Mouse $301.60Female or MaleHeterozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
$301.60Female or MaleHomozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  
Price per Pair (US dollars $)Pair Genotype
$603.20Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier  
$603.20Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Mice are subject to US Patent 6040430.
- Notice to customers in Canada.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)